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1. INTRODUCTION 
  Nature is the delightful example for the phenomena of symbiosis.  Natural products are 
origin from plants, animals, metals and minerals serving as the basis for the treatment of 
human disease. Medicinal plants based on tradition system of medicine have been playing an 
incredible role in providing diagnosis and treatment of human beings especially in developing 
countries. Utilization of herbal drug has also increased in developed countries. (1) 
 Herbal drug is the oldest form of health care known to mankind. Herbs had been used 
by all the cultures throughout the history. In modern civilization herbal drug is an integral 
part of the development. Primitive man observed and appreciated the great diversity of plants 
available to him. The most use of medicinal plant has been developed through observation of 
wild animal by trials and errors. As time moved on, each tribe added the medicinal power of 
herbs in their area based on their knowledge. They collected the information on herbs based 
on the method and well-defined it in herbal pharmacopoeia. Indeed, well into the 20th century 
most of the pharmacopoeia of scientific medicine was derived from the herbal lore of native 
place. Much of the drug commonly use now a day is of herbal origin. Most civilized country 
USA dispensed about 25% of prescription which contains at least one active ingredient 
derived from plant materials. Some are made from plant extract others are synthesized to 
mimic the natural plant compounds. (2) 
 From last five thousand years human being has relied on natural product as the primary 
source of medicines. However, the last two centuries have brought an explosion to 
understand how the natural products are produced and how they react with other organisms. 
The World Health Organization (WHO) estimates that 80% of the world health populations 
presently use herbal medicines for some aspect of primary health care (3). 
 In recent years synthetic drugs are showing more adverse affect, to overcome this 
problem researchers are trying to avoid this risk of those drugs.  Whenever a drug is 
prescribed to a patient they are facing risk of side effect, so long term use of these drugs 
patient should be careful.  But in herbal medicine the toxic effects are negligible, so the uses 
of herbal industry are growing up.  Indian, Chinese are using plant as medicine, as whole 
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plant or its extract. Toxicity of herbal drugs is less when compared with the synthetic 
medicines.4 
  India is known as a botanical garden in world and the largest producer of herbal 
medicines. India recognizes more than 3000 plant as medicinal use. It is estimated that more 
than 6000 plants in India are in use in traditional and herbal system of medicines.  Herbal 
medicines are used in various forms in indigenous system such as Unani, Ayurveda, and 
Siddha.5 
  Around 25,000 effective herbal formulations are used in traditional and folk medicine 
in India. The demand for plant products is increased throughout the world and the 
pharmaceutical companies are currently carrying out   research on plant material for the 
potential medicinal components.  Even though they are not able to prove the therapeutic 
effects of many plants, research continues to screen the active ingredients which form the 
basis of drugs to fight disease like psychological disorder, neuro-developmental disorder, 
diabetes, cancer, AIDS and various more chronic disease6. 
   In past years, the use of herbal drugs against various diseases as they are commonly 
non-toxic and have less side effects has developed. Even the World Health Organization 
(WHO) has recommended the effective use of plants in conditions wherever modern drugs 
are not safe 7. Sometimes, herbal preparation produces a good therapeutic response when 
given in combination with allopathic drugs. 
  The CNS disorders cause a range of complex, distress and life threatening symptoms 
some of which are not at all responsive. They generally leave the patient unable to function 
normally certain neuro transmitters cause neuro disorders such as ASD, Parkinsonism 
disease, myasthenia gravis, attention deficit disorders, epilepsy, anxiety myotropic lateral 
disease, multiple sclerosis8. 
 It is very important to use these medicines in a rational way.  On basis of traditional 
knowledge about medicinal use of plant as therapeutic agents a rational approach has been 
developed to use medicinal plants as lead for discovery of active molecules e.g. Gingko 
biloba extract can be as CNS stimulant9. 
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  In the modern research literature a number of clinical and experimental studies 
examine the potential herbs and formulae for ASD and related conditions. The classical 
literature contains herbal treatments for disorders that have symptoms and signs similar to 
those of ASD by combining and systematically evaluating the data derived from the modern 
and classical literature, it is expected that the herbs and formulae with the greatest potential for 
further research can be identified. 
  Considering the advantages of herbal drugs over the modern medicine and very keen 
to conserve the Indian traditional use of herbal products, the current project is designed, 
choosing the medicinal plant against autism spectrum disorder, the neuro-developmental 
disorder, where no proper evidence has been registered in use of herbal medicine. 
1.1. Neurodevelopment disorder10,11: 
  Impairment growth and development of brain or central nervous system are known 
as neurodevelopment disorders.  This term refers to a disorder of brain function that affects 
emotion, memory, self-control and ability of learning and that unfolds the individual grows. 
This term is exclusively used as a synonym of Autism and Autism spectrum disorder.  
   Disorders consider neuro-developmental in origin and that have neuro-
developmental consequence when occurs in infancy or childhood. This includes: 
Autism and Autism spectrum disorder such as Asperger syndrome. 
 Intellectual disability (ID) or intellectual and development disability (IDD). 
 Fetal alcohol spectrum disorder. 
 Traumatic brain injury (including congenital injuries which causes cerebral plasy).11 
 Motor disorders such as developmental coordination disorders, stereotypic 
movement disorder. 
 Communication, speech and language disorder. 
 Genetic disorder such as Fragile- X disorder. 
 Down syndrome. 
 Schizophrenia. 
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Neurodevelopmental disorders are associated with widely varying degrees of difficulty 
which are significant mental, physical, emotional and economical consequence for individual 
and it turn their family and society also. 
1.2. Cause: 12, 13 
  The development of brain is tightly regulated and genetically encoded process with 
clear influence from environment. This suggest that any deviation from this program early in 
life can result in neurodevelopment disorders and depending on specific timing, might lead to 
distinct pathology later in life 12. Because of that there are many causes of 
neurodevelopmental disorder, which can range from deprivation, genetic and metabolic 
diseases, immune disorder, infectious diseases, nutritional factor, physical trauma and 
environmental factors. 
 Some neurodevelopmental disorders are autism and other pervasive developmental 
disorders are considering multifactorial syndrome 13. 
Various causes of neurodevelopment disorder: 
 Immune disorder. 
 Infectious disorder. 
 Deprivation  
 Genetic diseases. 
 Metabolic diseases. 
  In early prenatal stage neurodevelopment start with a complex neurological 
development which begins with creation of neurons and radial glia and continue to develop in 
postnatal stage. This process will complete after 3yrs old. 
Migration of neurons, which occurs from the second to the six month of gestation and 
again within the cerebellum postnatal, is a very important and complex process. 
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Children neurodevelopmental and intellectual disorder 14,15 
Neurodevelopmental  Process 
 Abnormalities in maturation may underlie neurodevelopmental disorder. 
 Increased pruning with childhood –onset schizophrenia; decreased with autism. 
 
                         Fig.1. Neurodevelopment process in Human                
 
) 
 
 
 
 
Evaluation Of Hydro alcoholic Root Extract Of Withania somnifera Against Propionic Acid Induced 
Autism Spectrum Disorder In Mice 
 
Department of Pharmacology  
 Page 6 
 
 
 
 
1 in 6 children in the industrialized countries: 16 
 Cerebral plasy 
 Autism 
 Decreased IQ( intelligence quotient ) 
 ADHD ( attention deficit hyperactivity disorder) 
 Learning disabilities 
 Developmental delay  
 
 In industrialized countries neuro-developmental disorders occurs commonly. It has 
been figured that 15% of children’s are having learning disability, autism, ADHD, and 
developmental delay. The prevalence is much higher in aboriginal children. Although some 
cases are linked to identify the exposure e.g.; fetal alcohol, tobacco smoke, low birth weight 
and in many cases etiology is not known. 
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2. REVIEW AND LITERATURE:  
2.1 Autism Spectrum Disorder 
Autism is a neurodevelopment disorder which is characterized by impaired social 
interaction, verbal and non-verbal communication and repetitive behavior.  First two years of 
child hood parents can identify the sign of autism17. These signs are develop gradually, 
though some child’s with autism is reach their developmental target at normal pace and then 
degenerate18. The investigative criteria require that symptoms became apparent in early 
childhood, typically before age three19 
 Autism is a highly heritable diseases, researcher suspect both genetic fact as well as 
environmental fact as causes20, in rare case autism is strongly related with agent that cause 
birth defect21. Controversies envelop that other proposed environmental causes22 for example 
the vaccine hypothesis have been disproven.  Autism affects in order processing in the brain 
by altering how nerve cells and their synapses connect and organizes; how this occurs is not 
well unstated23. In the  DSM V it is one of three recognize disorders in the autism 
spectrum(ASDs), the other two being Asperger syndrome, which lacks delays in cognitive 
development and verbal communication and pervasive development disorder not otherwise 
specified , which is diagnosed when full set of criteria for autism or Asperger syndrome are 
not met24.  
  Behavioral intervention can help a child with autism gain self-care, communication 
and social skills17.  There is no known cure which has been reported on children who has 
recovered25.  Not many children with autism live independently after reaching old age, 
however some became successful26. An autistic culture has developed with some individual 
seeking a cure and others believing autism should not be treated as disorder, should be 
accepted as a difference27. 
Internationally autism is estimated to affect 21.7 million people as of 2013 28. As of 
2010, the number of people affected is expected at about 1-2 per 1000 worldwide. It occurs 
four to five times more than in boys than girls. About 1.5% of children in the United States 
are diagnosed with ASD as of 2014, an increase from one in 88 in 2012 29,30,31. The rate of 
autism among adults aged 18years and over in the United Kingdom is 1.1% 32.  The number 
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of people diagnosed has been increasing radically since the 1980s, partly due to change in 
diagnostic practice and government - subsidized economic incentives for named diagnoses33.  
1.2.Characteristic:   
    Autism is highly variable neurodevelopment disorder34 that first appears during 
infancy and childhood and generally follows a stable course without reduction35. People with 
autism may be severely impaired in some respect but normal or even advanced in others36. 
Evident symptoms gradually begin after the age of six months, became established by age 
two or three years37, and have a tendency to continue through adulthood, even though often in 
more muted form38. It is illustrious not by a single symptom, but by a characteristic triad of 
symptoms; impairments in social interaction, impairments in communications and restricted     
interest and repetitive behavior. Other aspects, such as atypical eating are also common but 
are not essential for diagnosis39. Autism individual symptoms occur in the general population 
and appear not too associated highly, without a sharp line separating severe from common 
trials40. 
Characteristic includes; 
 Social development 
 Communications 
 Repetitive / restricted behaviour41 
 Stereotype 
 Compulsive behaviour 
 Sameness 
 Ritualistic behaviour 
 Self-injury (skin picking, hand biting, eye pocking). 
 Other symptoms:42 
 Poor motor planning 
 Poor muscle tone 
 Toe walking 
 Sensory abnormalities 
 Stress  
 Sensation seeking. 
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                             Fig 2: Schematic represents action of autism       
 
1.3  Pathophysiology Of Autism: 
 Different scores of other brain disorders such as Parkinson’s, autism does not have a 
apparent unifying mechanism at either the molecular, cellular or system level; it is not known 
whether autism is a few disorders caused by mutations converging on a few common 
molecular pathways, or is a large set of disorders with miscellaneous mechanism34. Autism 
appears to result from developmental factors that affect many or all functional brain 
systems43, and to disturb the timing of brain development more than a final product44. Neuro-
anatomical studies connected with teratogens strongly suggest that autism’s mechanism 
includes alteration of brain development rapidly after conception. This variance appears to 
start a cascade of pathological events in the brain that are radically influenced by 
environmental factors45. Just after birth the brain of children with autism have a tendency to 
grow faster than usual, followed by normal or moderately slower growth in childhood. It is 
not known whether early overgrowth occurs in all children with autism. It seems to be most 
well-known in brain areas underlying the development of higher cognitive specialization. 
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Hypotheses for the cellular and molecular bases of pathological early overgrowth include the 
following:  
o An overload of neurons that causes local more than connectivity in brain region46. 
o Disturbed neuronal migration during early gestation47, 48. 
o Unbalanced excitatory-inhibitory networks48. 
o Abnormal formation of synapses and dendrites spines48. 
 
                         Fig3: Autism affects on various parts of brain44. 
 
 
 
 The immune system is thought to play an important role in autism. Children with 
autism have been found by researchers to have inflammation of both the peripheral and 
central immune system as indicated by increased levels of pro-inflammatory cytokines and 
significant activation of microglia 49, 50, 51. Biomarkers of abnormal immune function also 
have been associated with increased impairments in behaviors that are characteristic of the 
core feature of autism such as deficits in social interactions and communications 50. 
Interaction between the immune system and nervous system is said to start during the 
emergent stage of life and successful neurodevelopment depends on a balanced immune 
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response. It is through that activation of pregnant mother’s immune system such as from 
environmental toxicants or infection can contribute to causing autism through causing a 
disruption of brain development 52, 53, 54. This is supported by recent studies that have found 
that infection during pregnancy is associated with an increased risk of autism 55, 56.   
The relationship of neuro-chemicals to autism is not well understood; several have 
been investigated, with most of the indication for role of serotonin and of genetic differences 
in its transfer23. The role of metabotropic glutamate receptors (mGluR) in the pathogenesis of 
Fragile X syndrome, the most ordinary identified genetic cause of autism, has led to interest 
in the possible implications for future autism research into this pathway57. Some data suggest 
neuronal overgrowth potentially related to an excess in numerous growth hormones58 or to 
impaired instruction of growth factor receptors. A few inherent errors of metabolism are 
associated with autism, but probably account for less than 5% of cases59. 
1.4  Causes: 
  Many causes of autism have been projected, but understanding of the theory of 
causation of autism and the autism spectrum disorders is imperfect 60. Research indicates that 
genetic factors dominate. The heritability of autism, though, is complex, and it is normally 
unclear which genes are dependable61. In rare cases autism is strongly connected with agents 
that cause birth defects62. Several other causes have been proposed, such as childhood 
vaccination, but frequent epidemiological studies have shown nonscientific evidence behind 
any link between vaccinations and autism63. 
 Although specific causes of autism spectrum disorders yet have been                found, 
several risk factor has been identified in the research journalism that may contribute to their 
development. This risk factor includes genetic, prenatal factors, neuro-anatomical 
abnormalities, and environmental factors. It is possible to identify general risk factors, but 
much more difficult to identify specific factors. In the current state of knowledge, prediction 
can only be a universal nature and therefore requires the use of general markers64. 
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Genetic risk factors 
 The report of family and twin studies state that genetic factor play an important role 
in the etiology of autism and other pervasive development disorders65. Studies have 
consistently found that the occurrence of autism in siblings of autistic children is 
approximately 15-30 times greater than the rate in the general population66. In addition, 
researchers suggest that there is a much higher concordance rate among monozygotic twins 
compared to dizygotic twins 67. It appears that there is no single gene that can account for 
autism.  There are multiple genes involved, each of which is a risk factor for components of 
the ASD 68, 69 70. 
Prenatal and perinatal risk factors 
  Numerous prenatal and perinatal complications have been reported as possible risk 
factors for autism. These risk factors includes maternal gestational diabetes, maternal and 
paternal age over 30, bleeding after first trimester, use of prescription medication(e.g. 
velporate) during pregnancy and meconium in amniotic fluid. Whereas research is not 
conclusive on the relation of these factors to autism, each of these factors has been identified 
more frequently in autistic children compared to their non-autistic siblings and other usually 
developing youth 71.  
  Vaccine controversy: 
 The most controversial claim concerning autism etiology was the ‘vaccine 
controversy ’72  this speculate, arising from a case of scientific misconduct 73,  suggested that 
autism result from brain damage caused either by (1) measles, mumps, rubella (MMR) 
vaccine or by (2) thimerosal, a vaccine preservative 74. No credible scientific support these 
claims and further indication continues to regulate them, including the observation that the 
rate of autism continues to climb despite exclusion of thimerosal from routine childhood 
vaccine 75. A 2014 meta- analysis examined ten major studies on autism and vaccines 
connecting 1.25 million children worldwide; it included that neither the MMR vaccine, which 
has never contained thimerosal 76,  nor the vaccine components thimerosal or mercury, lead to 
the development of ASDs 77.         
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      2.5. History & Nomenclature:     
 The New Latin word autimus (English translation autism) was coined by the Swiss 
psychiatrist Eugen Bleuler in 1910 as he was defining symptoms of schizophrenia. He 
derived it from the Greek word autos (autos meaning”self’’), and used it to mean morose 
self-admiration, referring to autistic withdrawal of the patient to his fantasies, against which 
any influence from outside becomes an unbearable disturbance 78.   
The word autism first took its modern sense in 1938 when Has Asperger of the 
Vienna University Hospital adopted Bleuler’s terminology autistic psychopaths in a lecture in 
German about child psychology 79. Asperger was investigate an ASD now known as 
Asperger syndrome through for various reasons it was not widely recognize as a separate 
diagnosis until1981 80. Leo Kanner of the Johns Hopkins Hospital first used autism in the 
modern sense in English when he introduced the label early infantile autism in a 1943 report 
of 11 children with striking behavioral similarities. Almost all the characteristics described in 
Kanner’s first paper on the subject notably ‘autistic aloneness” and ‘‘insistence on 
sameness”, are still consider as typical of the autistic spectrum disorders. It is not known 
whether Kanner derived term independently of Asperger81. 
  Kenner’s reuse of autism led to decades of confused terminology like infantile 
schizophrenia, and child psychiatry’s focus on maternal deprivation led to misconceptions of 
autism as an infant’s response to’’ refrigerator mothers’’. Starting in the late 1960s autism 
was recognized as a separate syndrome by representing that it is lifelong distinguishing it 
from intellectual disability and schizophrenia and from other developmental disorder, and 
demonstrating the benefits of involving parents in active programs of therapy82. As late as the 
mid-1970s there was little evidence of a genetic role in autism; now it is thought to be one of 
the most heritable of all psychiatric conditions83. Even though the rise of parent association 
and the destigmatization of childhood ASD have extremely affected how we view ASD, 
parents continue to feel social sigma in situations where their child’s autistic behavior is 
perceived negatively by others84, and many primary care physicians and medical specialists 
still express some viewpoint consistent with outdated autism research 85. 
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2.6. Different Types of ASD: 86, 87  
(ASD also known as pervasive developmental disorders) 
According to the National Institutes of Health, “The diagnostic category of pervassive 
developmental disorders (PDD) refers to group of disorders characterized by delays in the 
development of socialization and communication skills.” In fact, that group of disorder is 
identical with disorders otherwise known as autism spectrum disorders. They include:  
 Asperger’s  Disorder  
 Rett’s  Syndrome  
 Childhood Disintegrative Disorder  
 PDD-NOS 
 Autistic Disorder. 
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Rett’s Syndrome 
Rett’s syndrome is a genetic disorder that affects only girls. It is the only one of the 
former autism spectrum disorders that can be diagnosed medically (so far) and as of 
May 2013, it is no longer included in the Autism Spectrum. Girls with Rett syndrome 
develop severe symptoms including the characteristic social communication challenges of 
autism. 
PDD-NOS 
  "Pervasive Developmental Disorder Not Otherwise Specified" is a mouthful of 
words that are often applied to people on the autism spectrum. It describes individuals who 
don't fully fit the criteria for other specific diagnoses but are nevertheless autistic. Because 
there is no easy way to define the symptoms of PDD-NOS, which may range from very mild 
to very severe, the diagnostic category no longer exists, though a new diagnosis, Social 
Communication Disorder, may become a similar "catchall" category. 
Asperger’s Syndrome 
Asperger’s syndrome   is the mildest form of autism, these affects boys three times more 
than girls. Children with AS became obsessively interested in a single object or topic. They often 
learn all about their favored subject and discuss it nonstop. Their social skills though are 
markedly impaired, and they are awkward and uncoordinated. 
 Asperger's syndrome is mild compared to other ASDs. Also, children with AS frequently 
have normal to above average intelligence. As a result, some doctors call it "high-functioning 
autism." As children with AS enter adulthood, though, they are at high risk for anxiety 
and depression. 
Autistic disorder 
Children who assemble more rigid criteria for a diagnosis of autism have autistic disorder. 
They have more severe impairments involving social and language functioning, as well as 
repetitive behaviors. Often, they also have mental retardation and seizures. 
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Childhood Disintegrative Disorder 
 The most severe autistic spectrum disorder, childhood disintegrative disorder (CDD), is 
also the least common. 
 After a period of normal development, usually between ages 2 and 4, a child with CDD 
rapidly loses multiple areas of function. Social and language skills are lost, as well as intellectual 
abilities. Often, the child develops a seizure disorder. Children with childhood disintegrative 
disorder are severely impaired and don't recover their lost function. 
 Fewer than two children per 100,000 with an autistic spectrum disorder meet criteria for 
childhood disintegrative disorder. Boys are affected by CDD more often than girls. 
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2.7. Epidemiology: 88-90 
 In recent review have a tendency to estimate a prevalence of 1-2 per 1000 for autism and 
close to 6 per 1000 for ASD and 11 per 1000 children in the United States for ASD as of 
2008   because of inadequate data, these numbers may underestimate ASDs true rate. 
Worldwide, autism affects an estimated 21.7 million people as of 2013, while Asperger 
syndrome affects a further 31.1 million. In 2012, the NHS estimated that the overall 
prevalence of autism among adults aged 18 years and over in the UK was 1.1%.  Rates of 
PDD-NOS’s have been estimated at 3.7 per 1000 Asperger syndrome at approximately 0.6 
per 1000 and childhood disintegrative disorder at 0.02 per 1000.  CDC’s mainly recent 
estimation is that 1 out of every 68 children, or 14.7 per 1000, has ASD as of 2010 
Graph 1: Reports of autism cases per 1,000 children grew dramatically in the U.S. 
from 1996 to 2007 
                         
Several other conditions are common in children with autism. They include: 
Genetic Disorder: 91,92 
Around 10-15% autism cases have a particular single-gene condition, chromosomes 
abnormality or other genetic syndrome, and ASD is associated with various genetic disorders. 
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Intellectual Disability.93, 94,95         
  Several studies have been reported 25-70 percentage of autistic individuals who also 
meet criteria for intellectual disability, a wide variation illustrating the difficulty of assessing 
autistic intelligence. Intellectual disability is much weaker compared with PDD-NOS 
association. 
Anxiety Disorders: 96 
  In ASD anxiety disorder is common in children, there is no firm data but studies 
have been reported prevalence ranging from 11-84%.  Most of the anxiety disorders have 
symptoms that are better explained by ASD or are hard to distinguish from ASD’s symptoms.  
   Epilepsy97:Variations in risk of epilepsy due to age, cognitive level, and type of language 
disorder. 
 Metabolic defects such as phenylketonuria are associated with autistic symptoms. 
  Minor physical anomalies98 are significantly increased in the autistic population. 
 Preempted diagnosis 99 Even though the DSM-IV rules out concurrent diagnosis of many 
others conditions along with autism, the full criteria for Attention deficit hyperactivity 
disorder (ADHD) Tourette syndrome, and other of these conditions are frequently present 
and these comorbid diagnoses are increasingly accepted. 
 Sleep problems100 affect about two-thirds of individuals with ASD at some point in 
childhood. The most commonly include symptoms of insomnia such as difficulty in falling 
asleep, frequent nocturnal awakenings, and early morning awakenings.  
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  2.8. Screening And Diagnosis: 101 
Diagnosing of autism spectrum disorder (ASD) is difficult, since there is no medical 
test, like a blood test, to diagnose the disorders. Doctors look at the child’s behavior and 
development to make a diagnosis. 
 Sometimes ASD can be detected at 18 months or younger. At an age 2, a diagnosis 
by an experienced professional can be considered very dependable. Though, many children 
do not receive a final diagnosis until much older. This delay means that children with an ASD 
might not get the help they need. 
Diagnosing an ASD takes two steps: 
 Developmental Screening 
 Comprehensive Diagnostic Evaluation 
  
Developmental Screening 
 Developmental screening is a small test to inform about children is learning basic skills when 
they should, or if they might have delays. During developmental screening the physician may 
ask the parents about the child’s behavior, learning ability and movements etc. a delay of this 
area could be a sign of a problem. 
   All children should be screened for developmental delays and disabilities during 
regular well-child physician visits at: 
 9 months 
 18 months 
 24 or 30 months 
 Additional screening might be needed if a child is at high risk for developmental 
problems due to preterm birth, low birth weight or other reasons. 
  In addition, all children should be screened specifically for ASD during regular well-
child doctor visits at: 
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 18 months 
 24 months 
 Additional screening might be needed if a child is at high risk for ASD (e.g., having a 
sister, brother or other family member with an ASD) or if behaviors sometimes 
associated with ASD are present 
If any signs of a problem found by physician, then a comprehensive diagnostic 
evaluation is needed. 
Comprehensive Diagnostic Evaluation 
Comprehensive evaluation is a second step of diagnosis. This review may include 
looking at the child’s behavior and development and interview the parents. It may also 
include a hearing and vision screening, genetic testing, neurological testing, and other 
medical testing. 
In several cases, the primary care might decide to refer the child and family to a 
specialist for further assessment and diagnosis. Specialists who can perform evaluation 
include: 
 Developmental Pediatricians (doctors who have special training in child development 
and children with special needs) 
 Child Neurologists (doctors who work on the brain, spine, and nerves) 
 Child Psychologists or Psychiatrists (doctors who know about the human mind) 
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             Fig4: Parts of brain affected by Autism 
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   2.9. Treatment 102-107 
   Different types of treatments are accessible to treat ASD. For example: facilitated 
communication, auditory training, vitamin therapy, anti-yeast therapy, physical therapy, 
occupational therapy, and sensory integration. 
The treatments can be generally categorized as follows: 
    Curriculum development 
     Dietary Approaches 
   Pharmacotherapy 
   Complementary and Alternative Medicine  
Curriculum development  
Based on the child’s unique pattern of strengths and weaknesses, educational 
interventions must be individualized. Comprehensive educational plans for a child with ASD 
include the following areas: social skills, communication, cognitive skills, and adaptive 
behaviors’, sensory and motor development. 
Dietary Approaches  
Removing certain types of foods especially those are rich in gluten and casein from a 
child’s diet and using vitamins like B12 or mineral supplements improve the behaviors’ being 
aggressive. Dietary treatments are based on food allergies or lack of vitamins and minerals 
that cause symptoms of ASD.  
Complementary and Alternative Treatments 
To relieve the symptoms of ASDs, some health care professionals provide them 
complementary and alternative medicine (CAM). It includes special diets, biological (e.g., 
secreting), chelation (to remove heavy metals like lead from the body), or body-based 
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systems (like deep pressure, Acupuncture), Vitamins like B12, Folic acid, Omega-3, and 
Melatonin to improve sleep cycle. 
Pharmacotherapy  
There are no medications available that can cure ASD or treat the core 
symptoms. However, there are few medications to help people with ASD function better. 
Medication may help in managing inability to focus, high energy levels, depression or 
seizures. But all medications may not affect all autistic individuals in the same way.  
It is important that there are no medications still to target social and language 
impairment of autism specifically. Medications usually used to control the 
symptoms are: 
 Risperidone and aripiprazole - approved by the FDA for the treatment of 
irritability associated with ASD.108 
o Risperidone is a dopamine D2 or serotonin (5HT) receptor antagonist and have 
powerful antipsychotic properties. It has a greater risk of weight gain. 
o Aripiprazole is also an antipsychotic agent with high affinity towards serotonin 5-
HT1A and 5-HT2A receptors and dopamine D2 and D3 receptors. It has a relatively 
lower risk for weight gain. 
 Citalopram, an antidepressant drug has no effect against ASD instead showed 
serious adverse effects like hyperactivity, impulsiveness, stereotypy and decreased 
concentration109.
 
 Fluoxetine is also an antidepressant drug but it has been related with improvements 
in stereotypy, irritability, lethargy, and inappropriate speech and improved 
functioning of behaviors in persons with ASD or mental retardation have been 
observed.110,111
 
 Fluvoxamine is used for reducing repetitive thoughts and behavior, aggression, and 
in improvement in some aspects of social relatedness, especially language usage. 
Side effects like Mild sedation and nausea are reported.112
 
 Venlafaxine is a potent inhibitor of 5-HT, norepinephrine and to a lesser extent, 
dopamine reuptake. It improves repetitive behaviors, hyperactivity, communication, 
inattention113
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 Lithium or other mood stabilizers are used rarely in treating cyclic irritability and 
explosiveness associated with ASD.114 
 Stimulants showed short attention span, impulsivity, and hyperactivity in some 
autistic individuals; however they may worsen the stereotypies and behavior in some 
individuals with ASD115.  
 The hyper arousal behaviors such as stereotypic movements, hyperactivity, and self-
stimulation evident with many individuals are treated with clonidine, a α2 
adrenergic receptor agonist. Side effects like sedation and fatigue were not noted but 
develop tolerance to sedatives but not the therapeutic effects of clonidine. 116,117 
 Propranolol (beta blockers) is used in the management of aggression, agitation and 
anxiety. Since the half-life of this drug is short (~ 4 hrs), frequent administration is 
necessary. Hypotension and bradycardia occurs as side effects.118  
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2.10. Experimental Animal Models For Autism Spectrum Disorder 
Mechanical induced ASD 
ASD model on macaque monkeys 119. 
This is the most successful model developed till date. It involves the removal of 
bilateral removal of the medial temporal lobe of young macaque monkeys. The animal shows 
a svariety of social and emotional changes like human including social isolation. It also 
demonstrates other autistic symptoms such as stereotypical behaviors. 
Early lesions of cerebellum, amygdala and medial prefrontal cortex also induce ASD 
 Chemical induced ASD  
In utero exposure to thalidomide and valproic acid 120,121 
In this model rats are prenatally exposed to terotogens (like thalidomide and valproic acid).   
In utero exposure to teratogens in the 1st trimester (12th day of gestation) of rat affects the 
cranial nerve nuclei and motor nuclei of foetus resembling neuropathology of Autism 
spectrum disorder in human. 
Propionic acid induced ASD  
Propionic acid is produced by gut bacteria such as clostridia and propionic bacteria. 
Intracerebro ventricular (icv) infusion of propionic acid produces ASD symptoms in rodents. 
Infection induced ASD 
Neonatal Borna Disease virus (BDV) infection 122 
Many of the features of pathogenesis, expression of neuro-anatomical and behavioral 
disease in neonatally BDV infected rats resemble ASD. Persistent infection of BDV on brain 
of neonate rat affects hippocampus which produces deficits in emotional and cognitive 
domains. It also causes metabolic alterations in selective neuronal populations without a 
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gross injury. BDV infection allows us to study the brain-behavioral relationship from a 
developmental standpoint. 
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2.11. INTRACEREBRO VENTRICULAR INFUSION OF PROPIONIC ACID (PPA): 
                 ASD EXPERIMENTAL ANIMAL MODEL123 
Introduction 
An emerging possibility is that ASD is a systematic encephalopathic condition 
involving digestive, immune and metabolic dysfunction exacerbated by environmental 
triggers. ASD patients have high levels of Clostridia or Bacterioidetes in the gut, which 
produce propionic acid (PPA) and other fatty acids by anaerobic fermentation of dietary 
carbohydrates and some amino acids. 
Propionic acid (PPA) is a short chain fatty acid that is endogenous to the human body 
as both an intermediary of fatty acid metabolism and a metabolic end product of enteric gut 
bacteria, Clostridia and Propionibacteria, a common food preservative in refined wheat and 
dairy products. PPA, being a weak acid, exists in both aqueous and lipid soluble forms and 
can readily enter the systemic and CNS environments (blood–brain barrier) both via 
monocarboxylate transporters and can cause health-related issues if the individual is unable to 
metabolize short-chain fatty acids adequately. PPA and other short-chain fatty acids (i.e. 
butyrate and acetate), affect diverse physiological processes such as neurotransmitter 
synthesis and release, cell signaling, lipid metabolism, immune functions, mitochondrial 
function, gap junctional gatin, and modulation of gene expression through DNA methylation 
and histone acetylation.  
Mechanism of action 
PPA is known to increase intracellular neuronal and glial acidification. It also 
increases calcium proportions, thereby affects neurotransmitter release including serotonin, 
dopamine, glutamate, and norepinepherine each of which play a role in elicitation of 
abnormal behavior and locomotor activity. PPA has been shown to increase glutamatergic 
transmission, leading to excitability in brain regions linked to locomotor activity.  
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Fig 5: Communication pathway between propionic acid of gut microbiota and 
neurotransmitters and inflammatory mediators 
 
 
Phospholipids are the major structural components of neuronal and other cellular 
membranes, and include phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylinositol (PI), and sphingomyelin (SM). All of these 
phospholipid classes were observed to have altered molecular species distribution following 
PPA infusion. The pathological consequences of disturbances in phospholipid metabolism 
could include alterations in signal transduction involving the generation of second 
messengers derived from arachidonic and docosahexaenoic. The observation that PPA 
infusion increased the proportions of brain PI and PC molecular species containing 
arachidonic acid and decreased the proportions of PS and PE molecular species with 
docosahexaenoic acid, suggests that PPA could influence the innate neuroinflammatory 
process observed in ASD. Eicosanoids are inflammatory mediators that induce the formation 
Propionic acid 
Source:  http://www.nature.com/nrn/journal/v13/n10/images/nrn3346-f1.jpg 
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of proinflammatory cytokines such as tumor necrosis factor (TNF), interleukin 1 (IL-1), and 
interleukin 6 (IL-6). The increased accumulation of brain molecular species with the 
eicosanoids precursor (arachidonic acid) and the decreased proportions of the molecular 
species, containing the docosanoids precursor (docosahexaenoic acid) increase 
neuroinflammation. In both brain and blood membranes, PPA infusions alter the PC and PE 
composition (both diacyl and plasmalogen forms). The alterations observed in plasmalogen 
molecular species in brain and blood polyunsaturated PE and PC molecular species, increases 
oxidation following PPA infusions. 
PPA is known to reversibly inhibit mitochondrial function via the production of the 
cytotoxin propionyl Coenzyme A and through the sequestration of carnitine, leading to 
impairments in fatty acid metabolism. Both of these effects could lead to a diffuse 
encephalopathic process due to an intercellular accumulation of PPA and other fatty acids, 
with resultant increases in oxidative stress. Oxidative damage of lipids has been suggested to 
play a part in the pathogenesis of many neurological diseases. Oxidative damage has been 
shown to uncouple the gap junctions in astrocytes. Arachidonic and docosahexaenoic acids 
which are very susceptible to oxidative damage have been shown to modulate the coupling 
capacity of gap junctions. 
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2.12. Literature Review Of Autism Spectrum Disorder 
1. Screening And Diagnosis Of Autism.124 
  Filipek, P.A et.al has discussed about the current criteria for identifying and 
diagnosing autism spectrum disorders and the experimental evidence in which they are based. 
The authors also provide recommendations for a dual process approach of routine 
developmental observation to identify children at-risk for any developmental disorders and 
those exclusively at-risk for autism spectrum disorders and, secondly, to identify aspects 
individual autism from other developmental disorders. 
2. Autism: An Emerging ‘Neuroimmune Disorder’ In Search Of Therapy125 
Duraisamy Kempuraj et al have reviewed epidemiology, pathogenesis and treatment 
of ASD and suggested increased oxidative stress and immune dysregulation are present in 
ASDs. They also suggested that Mast cell activation may contribute to gut–blood–brain 
barrier disruption and brain inflammation.  
3. Hearing-impaired autistic children126 
Jure, R,et al have reviewed audio-logical information for a group of 46 children 
diagnosed with both austism and hearing loss. They concluded that while the severity of the 
autism diagnosis was related to the cognitive dysfunction, it was not linked to the severity of 
the hearing loss. Moreover, the review noted that almost 25% of the children remained 
undiagnosed with autism for a period of at least 4 years. 
4. Alterations of GABAergic Signaling in Autism Spectrum Disorders127 
Enrico Cherubini and Rocco Pizzarelli summarized that ASDs are associated with 
single mutations in genes encoding for neuroligin-neurexin families. These molecules 
regulate trans-synaptic signaling contributing to maintain a proper excitatory/inhibitory (E/I) 
balance at the network level. GABA in adult life has been shown to depolarize and excite 
targeted cell through an outwardly directed flux of chloride. In early development of life, 
GABA has a functional role in building up and refining neuronal circuits and the molecular 
mechanisms regulating the excitatory/Inhibitory, E/I balance. A dysfunction of the 
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GABAergic signaling early in development leads to a severe E/I unbalance in neuronal 
circuits, a condition that may account for some of the behavioral deficits observed in ASD 
patients. 
5. Peripheral auditory asymmetry in infantile autism.128 
Khalfa, S.,et al. explored the contra lateral suppression of otoacoustic emissions in 
individuals with autism and age- and gender-matched typically-developing individuals. 
Inhibition of otoacoustic emissions is hypothesized to result from activity of the efferent 
medial-olivo-cochlear pathway and is thought to be concerned in the filtering of background 
noise. Results of the study demonstrated differing patterns of irregularity between groups as 
well as an age-related decrease in otoacoustic emission amplitude among autistic individuals. 
The authors conclude that the findings may suggest involvement of higher-level processes as 
well as an age-related decrease in outer hair cell function among autistic individuals. 
 6. Parental Self-perception in the Autistic Spectrum Disorder Literature: a systematic 
Mixed Studies Review.129 
Kirsten K Frantzen et al. Illustrates that self-efficacy can be merged into 
competence and the emergence of the coherence construct. Competence, control, and 
coherence are vitally important core concepts for understanding parents of children with 
autism. A unified nomenclature based upon the overarching concept of self-perception 
would organize the most pivotal constructs much more clearly and reduce redundancies. 
Specifically, the concept of “parental self-perception” is the most promising candidate for 
this super ordinate concept.  
7. Melatonin In Autism Spectrum Disorders: A Systematic Review And Meta-Analysis 
130
 
Daniel A Rossignol and Richard E Frye investigated melatonin-related findings in autism 
spectrum disorders (ASD). They observed abnormality in melatonin and melatonin 
metabolite. The physiological levels of melatonin and ⁄ or melatonin derivatives were found 
to be below average. Gene abnormalities could contribute to decreased melatonin production 
or adversely affect melatonin receptor function in a small percentage of children with ASD. 
Clinical study reported improved daytime behavior with melatonin use 
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8. Brain Imaging Increases Our Understanding of Developmental Coordination 
Disorder: a Review of Literature and Future Directions 131 
Meisan Brown-Lum1   &Jill G. Zwicker suggested that children with 
developmental coordination disorder (DCD) activate different regions of the brain during 
functional tasks and show differences in white matter microstructure compared to typically 
developing children. The emerging neuro- imaging data will help clarify the possible 
underlying mechanisms in relation to impaired motor function at the behavioural level in 
children with DCD. 
9. Advances in the Research of Melatonin in Autistic Spectrum Disorder: Literature 
Review and New Perspective 132 
Sylvie Tordjman et.al   first reviewed the studies on melatonin levels and the 
treatment studies of melatonin in autistic disorder. After that they discussed about the 
relationship between melatonin and autistic behavioural impairments with regard to social 
communications (verbal, non-verbal communications, social interaction), and repetitive 
behaviours or interests with difficulties adapting necessary to established potential 
therapeutic efficacy of melatonin for social communication impairments and stereotyped 
behaviours or interests. 
10. Brain Serotonin And Dopamine Transporter Bindings In Adults With High 
Functioning Autism 133 
Kazuhiko Nakamura et al determined the occurrence of changes in the binding of 
serotonin and dopamine transporters, which are highly selective markers for their respective 
neuronal systems. They observed that Serotonin transporter binding was significantly lower 
throughout the brain in autistic Individuals. Specifically, the reduction in the anterior and 
posterior cingulated cortices was associated with the impairment of social cognition in the 
autistic subjects. Significant correlation was also found between repetitive and/or obsessive 
behavior and interests and the reduction of serotonin transporter binding in the thalamus. In 
contrast, the dopamine transporter binding was significantly higher in the orbito-frontal 
cortex of the autistic group. In the orbitofrontal cortex, the dopamine transporter binding was 
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significantly inversely correlated with serotonin transporter binding. The present findings 
indicate that the gross abnormalities in these neurotransmitter systems may underpin the 
neurophysiologic mechanism of autism. 
 11. Neuroimmunology of Autism Spectrum Disorder134 
David Marc & Kelly Olson summarized the role of cytokines in the patho-
physiology of autism has been researched suggesting a relationship with altered blood-brain 
barrier permeability and subsequent neuro-inflammation. Cytokine recruitment to the CNS 
may result in altered neurotransmitter signaling and the behavioral manifestation of autism 
symptoms. Other immune mediated events such as changes in the number and activity of 
natural killer cells, macrophages, immune-globulins, and glutathione may contribute to 
altered neuronal signaling and neurotransmitter imbalances.  
12. Autism And Immunity: Revisited Study.135 
Kempuraj DJ et al had a consistent finding in autistic children that a high number of 
mast cells and a high level of serotonin were even found at elevated concentrations in the 
urine of autistic patients. In addition, a dysfunction of gastrointestinal and immunological 
symptoms is noted in autistic children. It was suggested that an increase of 
cytokines/chemokines produced by mast cells at an early age may play an important role.  
13. Effects Of The Enteric Bacterial Metabolic Product Propionic Acid On Object-
Directed Behavior, Social Behavior, Cognition, And Neuro-Inflammation In Adolescent 
Rats: Relevance To Autism Spectrum Disorder.136 
Donald P, Derrick F. Mac Fabe et al administered propionic acid (PPA), a short 
chain fatty acid that is used as a food preservative and also is a metabolic end-product of 
enteric bacteria in the gut, to adolescent (41±4 days) male rats in a study of 
restricted/repetitive behavior, social behavior, and cognition. They evaluated the effects of 
PPA in young rodents. PPA (1µl of 0.26M solution) was administered intracerebro 
ventricularly prior to each behavioral test. Rats treated with PPA displayed restricted 
behavioral interest to a specific object among a group of objects, impaired social behavior. 
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14. Increased Serum Levels Of Glutamate In Adult Patients With Autism.137 
Shinohe A et al studied whether amino acids (glutamate, glutamine, glycine, D-
serine, and L-serine) related to glutamatergic neurotransmission is altered in serum of adult 
patients with autism. Serum levels of glutamate in the patients with autism were significantly 
higher than those of normal controls. In contrast, serum levels of other amino acids 
(glutamine, glycine, d-serine, l-serine) in the patients with autism did not differ from those of 
normal controls. The study suggested that an abnormality in glutamatergic neurotransmission 
may play a role in the pathophysiology of autism. 
15. Oxidative Stress Markers in Children with Autism Spectrum Disorders 138 
María Elena González-Fraguela et al quantified the activity of the antioxidant 
enzyme catalase (CAT), glutathione concentration (GSH) and markers of damage to 
biomolecules, malonyldialdehyde (MDA) and 8–hydroxy-2deoxyguanosine (8OHdG) in 
peripheral blood samples of ASD affected children to evaluate redox status. The study 
suggested that the total GSH content in autistic patients was significantly lower compared 
with the control group. Higher serum CAT, MDA and 8OHdG levels were found in children 
with autism compared with controls. The study supported the notion that oxidative stress is 
associated with autism. 
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3. PLANT PROFILE 
Introduction 
  Plants are the most important source of medicine in the world and writing indicates 
their medicinal uses as old as 4000-500 B.C.  In china first start use of herbal preparations as 
medicine.  In –India Rig-Veda (written between 3500-1600) having earliest source of plant as 
medicine, and after that the properties and therapeutically uses are recorded in Ayurveda139. 
World Health Organization has listed 20,000 species of medicinal plants which are used in 
universal140. 
According to WHO more than 80% of World population relies from primary health 
care by using traditional herbal medicines141. Various drugs & chemicals are obtain from 
various parts of plants and continue to be possible sources of new drugs and chemicals 143, 144. 
Withania somnifera (L) Dunal is an important medicinal plant and used in Ayurvedic 
medicines for the treatment of many diseases 145 .    
  In Auyrveda it is known as Rasayana’ because it promote longevity, arrest ageing 
process, increase ability of individual to resist adverse ecological conditions146.  The steroidal 
lactones (withanolides) obtained from its roots are mainly responsible for its therapeutic 
activities and general health maintenances like immune-modulation, combinating infectious 
agent, anti-cancer, anti-epileptic, anti-ageing, antioxidant, hypoglycemic, memory enhancer 
and in common an effective adaptogen.   
History and Nomenclature 146: 
Withania somnifera (L) Dunal commonly known as” Ashwagandha”,” Asgandh “, 
and “ Winter cherry” belongs to family Solanaceae and widely distributed in warmer parts of 
the world. Genus Withania comprises 23 species including W. somnifera (L), Dunal and   
W.coagulans (L) Dunal having high therapeutic value which are used as “Rasavana” in 
Ayurvedic formulations.  
 Ashwagandha attains the special name because its roots smells like horse (“Ashwa ’’) 
and believe to provide power like horse when consumed.(Ashwa means 
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horse. Gandha means fragrance. It indicates the property-the strength and sexual vitality of 
the horse.) 
    In Vedas it is described as herbal tonic and health food & considered as “Indian 
Ginseng” because of its ginseng like health promoting effects. Ashwagandha improves 
energy and also memory by enhancing the brain and nervous function; shows anxiolytic 
effects, has hepatoprotective property, raises hemoglobin level and red blood cell count, 
improve the cell-mediated immunity; promotes strength and vitality along with positive 
sexual life and reproductive stability and act as a powerful adaptogen. 
Fig 6: Leaves and root of Withania somnifera 
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Botanical Classification 147-149 
Kingdom      :         Plantae 
Division       :         Angiosperms 
Class            :         Dicotiledoneae 
Order           :         Tubiflorae 
Family         :         Solanaceae 
Genus          :          Withania 
Species        :           somnifera 
Vernacular Name 
 Arabic            :       Kaknaj-e Hindi  
Bengali            :      Ashvaganda , Asvagandha 
English            :      Winter cherry  
Gujarati           :       Asan, Asana, Asoda, Asunda,  
Malayalam      :       Amukkiram, Pevetti 
Marathi           :       Askandha, Kanchuki, Tilli      
Odiya              :      Asugandha  
Persian           :      Asgandh Nagaori, Kaknaj-e- Hindi 
Sanskrit          :     Ashvagandha, Ash vakandika, Gandhapatri,  Palashaparni  
Tamil             :      Amukkira, Asubam, Asubagandhi  
Telugu            :     Penneru, Asvagandhi, Dommadolu, Pennerugadda 
Urdu               :      Asgand, Asgand Nagori. 
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Common Names  
  Winter cherry (Eng.); Bitterapelliefie , Geneesblaarbossie, koorshout (Afr.);  
Bofepha ( Sotho); Ubuvuma (xhosa); Ubuvimbha (Zulu); Ashwagandha (Hindi). 
 Geographical Distribution 146 
Withania somnifera is extensively circulated around the world from Southern 
Mediterranean region to the Canary Island and from South to East Africa; Jordan, Egypt, 
Sudan, Iran, Afghanistan, and Pakistan. In India the plant is growing wild in the North-
Western regions extend to the mountainous region of Punjab, Himachal Pradesh, and Jammu 
up to an altitude of 1500m. 
Description146 
 W. somnifera is an erect green, branched / unbranched herb with height up to 1.25m. 
The aerial parts like stem, leaves an calyx are covered with fine hairy tomentum. Its branches 
are rounded; leaves are simple, ovate, entire, shiny smooth and opposite; flowers are 
inconspicuous, greenish or yellow, in axillary umbellate cymes, bisexual; fruits is a berry in 
persistent calyx and seeds are small, flat, yellow, very light. During June-July seeds used to 
sown and the plants are favor sunny situation. It is susceptible to bacterial, fungal, viruses, 
and pest’s infections.  
Phytochemical Constituents 150 
 The main constituents of Ashwagandha are alkaloids and steroidal lactones.  Among 
the various alkaloids, withanine is the main constituent. The other alkaloids are somniferine, , 
somniferinine, withananine, pseudo-withanine, tropine, pseudo-tropine,choline, anaferine and 
anahydrine. 
   The leaves contain steroidal lactones, which are commonly called as 
“withanolides”. The withanolides have C28 steroidal nucleus with C9 side chain, having six 
membered lactone rings 
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Pharmacological and Bioactivities 146  
  In Ayurvedic medicine Ashwagandha is widely used, and is an important ingredient 
prescribed for a variety of musculoskeletal conditions like arthritis, rheumatism and also used 
as general tonic to increase energy, overall health and longevity.  
  For investigation of Ashwagandha property many pharmacological studies have 
been conducted such as antioxidant, anti-ageing, immunemodulatory, cardio-protective, 
neuro-protective etc.  It is most important plants in Indian pharmacopeia and World 
pharmacopeia. 
            Fig7: Pharmacological activities of Withania somnifera 
 
 
 
  
                              
 
            
 
     
 
 
  Traditional uses: 150 
Ashwagandha has sedative and hypnotic effects. It has hypotensive, respiratory, 
stimulant action along with bradycardia. It is an immunemodulatory agent. It acts as mood 
stabilizer revives mind and body. 
   Ashwagandha    
   
              
Immunemodulator
y
Neuro-protective               
Activity Antioxidant 
Anti-inflammatory  
 
Anti-cancerous activity 
Anti -diabetic 
Anti-stress/ Adaptogenic 
Anti-ageing 
Cardio-protective 
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  Traditionally it has been used in the treatment of rheumatism, gout, hypertension, 
nervine and skin diseases. This drug prevents bony degenerative changes in arthritis 
conditions. It has been widely used as sex stimulant and rejuvenator and is considered as 
strength & vigor promoting drug especially in geriatric cases.  
   The leaf extracts shows action against Staphylococcus aureus and Ranikhet virus. 
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3.1. Review and literature of Withania somnifera: 
1. Withania somnifera Improves Semen Quality 151 
Abbas Ali Mahdi et al has been carried out to understand the role of stress in male 
infertility and to rest the ability of W .somnifera to combat stress and treat male fertility. 
Various biochemical and stress parameters before and after treatment suggested a definite 
role of stress in male infertility and the ability of  W. somnifera to treat stress- related 
infertility. Treatment resulted in a decrease in stress, improved the level of anti-oxidants and 
improved overall semen quality in a significant number of individuals. The treatment resulted 
in pregnancy in the partners of 14% of the patients. 
2. Adaptogenic Activity Of The Roots Withania Somnifera Dun 152 
B. Singh et.al was evaluated for putative anti-stress activity against a sequence tests 
to delineate the activity of this fraction. The extract of Withania somnifera root was also used 
to compare the results. A preliminary acute toxicity study in mice showed a good margin of 
safety with a high therapeutic index. 
3. Anticancer activities of Withania somnifera 153 
 B. Yadav et.al evaluated in vitro cytotoxicity in 50% ethanol extract of root, stem 
and leaves of Withania somnifera against five human cancer cell lines of four different tissues 
i.e. PC-3, DU-145(prostrate), HCT-15 (colon), A-549 (lung) and IMR-32 (neuroblastoma). 
This investigation is the first report of the anticancer activity in various parts of Withania 
somnifera cultivated in fly ash amended soil. 
4. Immunomodulatory activity of Withania somnifera 154 
Girija Kuttan et al. designed that administration of an extract from the powdered 
root of the plant Withania somnifera was found to stimulate immunological activity in mice. 
Treatment with five doses of Withania somnifera root extracts (20mg/dose/animal:i.p.) was 
found to enhance the total WBC count on 10th day. Bone marrow cellularity as well as α-
esterase positive cell number also increased significantly after the administration of Withania 
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somnifera extract. The result proves the immunemodulatory activity of Withania somnifera 
extract, which is known immune-modulator in indigenous medicine. 
5. Cardio-protective Effect of Withania somnifera.155 
Ipseeta Mohanty et al.  designed to evaluate the cardio-protective potential of 
hydro-alcoholic extract of Withania somnifera the basis of haemodynamic, histopathological 
and biochemical parameters in the isoprenaline induced myocardial necrosis in rats and to 
compare with vitamin E, a known cardio-protective antioxidant. Among the different doses 
studied, Withania somnifera at 50mg/kg dose produced maximum cardio-protective effects. 
6. Hypoglycemic activity of Withania somnifera 156 
 Jonathan Gorelick et.al evaluated that in India Ashwagandha is used traditionally to 
treat many medical problems including diabetes and has verified therapeutic activity in 
various animal models as well as in diabetic patients. While much of W. somnifera 
therapeutic activity is attributed to Withanolides, their role in the anti-diabetic activity of W. 
somnifera has not been adequately studied. This study evaluated the anti-diabetic activity of 
W. somnifera extract and purified Withanolides as well as the effect of various elicitors on 
this activity. 
7.  Pharmacological profile of Withania somnifera (Ashwagandha) 157 
  Kaur Narinderpal et al. evaluated ashwagandha possesses antioxidant, anxiolytic, 
adaptogen, memory enhancing, antiparkinsonian, antivenom, antiinflammatory, antitumor 
properties. Various other effects like immunomodulation, hypolipidemic, antibacterial, 
cardiovascular protection, sexual behaviour, tolerance and dependence have also been 
studied. These results are very encouraging and indicate this herb should be studied more 
extensively to confirm these results and reveal other potential therapeutic effects. Clinical 
trials using ashwagandha for a variety of conditions should also be conducted. 
8. Effect of Withania somnifera in pulmonary hypertension 158 
 Kashif Hanif et al.  Studied the effect of W. somnifera root powder on 
monocrotanile induced PH in rats. This study demonstrated that W. somnifera significantly 
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protected against MCT-induced PH due to its antioxidant, anti-inflammatory, pro-apoptotic 
and cardio-protective properties. 
9. Neuro-protective effects of Withania somnifera 159 
 Muzamil Ahmad et al. have evaluated the anti-parkinsonian effects of Withania 
somnifera extract, which have been reported to have potent anti-oxidant, anti-proliferative 
and free radical quenching properties in various diseased conditions. W. somnifera extract 
was found to reverse all the parameters significantly in a dose-dependent manner. This study 
demonstrated that the extract of W. somnifera may be helpful in protecting the neuronal 
injury in Parkinson’s disease. 
.10. Protective effect of Withania somnifera root powder 160 
M. Rasooi et.al have been evaluate the protective effect of Withania somsnifera 
Dunal (family –Solanaceae), commonly known as Ashwagandha, on adjuvant-induced 
arthritis rats.  Results were compared with those for Indomethacin, a non-steroidal anti-
inflammatory drug. Arthritis was induced by intradermal injection of complete Freund’s 
adjuvant into right hind paw of Wister albino rats. The biochemical alterations observed 
were ameliorated significantly by oral administration of W. somnifera root powder 
(1000mg/kg body weight) in arthritis animals. The results of this study clearly indicate that 
W. somnifera root powder is capable of rectifying the biochemical changes in adjuvant 
arthritis. 
11. Withania somnifera on Orofacial – Dyskinesia 161 
  Pattipati S. Naidu et.al investigated the role of oxidative stress in the 
Pathophysiology of haloperidol (HP) - induced orofacial dyskinesia and evaluated the 
beneficial effect of Withania somnifera root extract in the amelioration of HP-induced 
vacuous chewing movements and tongue protrusions in the rat model for TD. These 
conclusions strongly suggest that oxidative stress plays a significant role in HP-induced 
orofacial Dyskinesia and that W. somnifera could be effective in preventing neuro-leptic 
induced extra pyramidal side effects. 
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12. Withania somnifera root extract expounds anti-inflammatory and muco-restorative 
activity 162 
Pankaj Pawar et.al investigates the beneficial effects of W. Somnifera in Trinitro 
Benzyl Sulfonic Acid (TNBS) induced experimental IBD through a rectally applicable 
formulation. Dose of the rectal gel applied at 1000 mf of WSRE per kg rat weight showed 
significant muco-resttorative efficacy in the IBD-induced rats, validated by histo- 
pathological studies. 
13. Identification of antifungal principle of Withania somnifera 163 
Susheel Kumar et al. studied the extracts of Chaetomium globosum EF18, isolated as 
endophytic fungus from Withania somnifera, and were found effective against Sclerotinia 
sclerotiorum. Ethyl acetate and methanol extracts were more effective than hexane extract 
showing >80% growth inhibition. Bioactive compound (antibiotic Sch 210971, m/z 445 and 
Ȝmax 290) having antifungal activity against S. sclerotiorum has been isolated in pure form 
from the ethyl acetate extract following bioassay guided fractionation.  Ethyl acetate extract 
was most active having IC50 value 35.4 ȝg/ml. 
14. Withania somnifera in neuro-behavioral disorder.164 
Sharanbasappa Durg et.al studied that a systematic search of the effect of W. 
somnifera on brain oxidative stress-induced neuronal pathology was performed using 
electronic databases. The systematic review was performed on neuro-behavioral parameters; 
whereas meta-analysis of W. somnifera effect was done oxidative stress marker (superoxide 
dismutase, catalase, and glutathione peroxidase glutathione and lipid peroxidation), nitrite, 
and protein carbonyl, AchE, ChAT and Ach of rodent brain. Data were analyzed using 
Review Manager Software. 
                The systematic review provides scientific evidence for the traditional claim of W. 
somnifera use in different neurological aliments. However, future clinical trials are mandated 
to establish the therapeutic efficacy and safety in human beings. 
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15. Anxiolytic-antidepressant activity of Withania somnifera.165 
S.K. Bhattacharya et al. investigated the anxiolytic and antidepressant actions of the 
bioactive glycol-withanolides, isolated from the roots of W. somnifera in rats. The 
investigation supports the use of WS as a mood stabilizer in clinical conditions of anxiety and 
depression in Ayurveda. 
16. Withania somnifera to improve Sexual Function 166 
  Swati Dongre et al. determined the efficacy and safety of a high-concentration 
Ashwagandha root extract (HCARE) supplementation for improving sexual function in 
healthy females. This study demonstrated that oral administration of HCARE may improve 
the sexual function in healthy women. 
 17. Withania somnifera on tests of cognitive and psychomotor performance167 
Usharani Pingali et.al: done an assessment of cognitive and psychomotor effects of 
Withania somnifera extract in healthy human participants. These results suggest that 
Withania somnifera extract can improve cognitive and psychomotor performance and 
therefore be a valuable adjunct in the treatment of diseases associated with cognitive 
impairment. 
18. Examination the effect of Withania somnifera supplementation on muscle strength 
and recovery: a randomized controlled trial 168. 
Wankhade et al. (2015) conducted to examine the possible effect of ashwagandha 
root extract consumption on muscle mass and strength in healthy men engaged in resistance 
training program. This study reports that Ashwagandha supplementation is associated with 
significant increase in muscle mass and strength & suggests that Ashwagandha 
supplementation may be useful in conjunction with a resistance training program. 
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4.  SCOPE OF WORK 
                   Autism is a neuro-developmental disorder that manifests early in childhood and it 
is the prevalence in world wide. . The average prevalence of ASD in Asia, Europe and North 
America was close to 1%. Management of Autism spectrum disorder is a global problem, 
successful treatment is very important for controlling the raising alarm of the disease. 
Till date there is no effective drug available to treat ASD. No herbal drug is proved to 
manage the severity of symptoms of Autism spectrum disorder. The objective of the present 
study is, to treat this disorder through nature in the form of herbal medicines or drugs with 
very minimal adverse effect. ASD among1994-99 born children who turned up adults now 
were reported with high prevalence. Hence the study was focused on autistic symptoms of 
adolescent age. 
The present study is designed to evaluate the effect of hydro-alcoholic root extract of 
Withania somnifera object-directed behavior, social behavior, cognition development and 
neuro-inflammation against propionic acid induced Autism Spectrum Disorder (ASD) in 
mice. So that it may serve clinically for the management of ASD.  
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5.   PLAN OF WORK:  
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6. METHODS AND MATERIALS: 
6.1. Collection and Authentication     
     The roots of Withania somnifera Dunal (Solanaceae) were collected from local 
source, Tamil Nadu (Chennai) in March. The plant material was identified and authenticated 
by Prof P. Jayaraman, PhD, Director: Professor, Presidency College, and Chennai 600005.   
PLANT ANATOMY RESEARCH CENTRE. Tambaram, Chennai-5, Tamilnadu. [NO: 
NISMB1592015]. A voucher specimen was submitted at C.L. Baid Metha College of 
Pharmacy, Chennai-97. 
6.2 Preparation of Hydro Alcoholic Root Extract of Withania somnifera 
The dried roots of Withania somnifera were collected. The dried root was made into 
coarse powder. The powdered roots of about 200g were extracted with hydro alcohol 
(ethanol/water – 80:20) in maceration process. After extraction the solvent was evaporated at 
40 ºC to obtain a viscous mass.  
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6.3 CHEMICALS: 
                 All the Chemicals used in the study were of analytical grade. The following 
chemicals were used for the experimental study.            
Table 1:  Name of the chemicals and their source  
 
       Sl .No 
 
MATERIALS 
 
   SOURCE 
1 Acetic acid S.d.fine chemicals Ltd, Mumbai 
2 Chloroform S.d.fine chemicals Ltd, Mumbai 
3 Disodium EDTA Chemspure, Chennai 
4 Distilled  water Andavar distilled water 
5 Ethanol Cisco research lab.Mumbai 
6 Fecl3 reagent S.d.fine chemicals Ltd, Mumbai 
7 Formaline S.d.fine chemicals Ltd., Mumbai 
8 Glacial acetic acid Chemspure, Chennai 
9 Glutathione oxidase Qualigens fine chemicals, Mumbai 
10 Glutathione reductase Qualigens fine chemicals,Mumbai 
11 Heptanes Loba chemicals Ltd, Mumbai 
12 Hydrochloric acid Loba chemicals Ltd, Mumbai 
13 Hydrogen peroxide Qualigens fine chemicals, Mumbai 
14 Iodine Chemspure, Chennai 
15 n-butanol S.d.fine chemicals Ltd, Mumbai 
             16 Nicotinamide adenine dinucleotide 
phosphate reduced tetra 
sodium(NADPH.Na4) 
S.d.fine chemicals Ltd, Mumbai 
17 Perchloric acid Loba chemicals Ltd, Mumbai 
18 Potassium chloride Chemspure, Chennai 
19 Potassium dihydrogen phosphate S.d.fine chemicals Ltd, Mumbai 
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              20 Propionic acid Merck Specialties private Ltd,Mumbai 
              21 
                  Pyridine Fischer inorganic&  aromatics Ltd, 
Chennai 
22 Sodium acetate S.d.fine chemicals Ltd, Mumbai 
23 Sodium azide S.d.fine chemicals Ltd, Mumbai 
24 Sodium chloride Paxy specialities Pvt Ltd 
25 
      Sodium dodecyl sulphate (SDS) S.d.fine chemicals Ltd, Mumbai 
26 Sodium hydrogen carbonate S.d.fine chemicals Ltd, Mumbai 
27 Sodium hydroxide pellets Chemspure, Chennai 
28 Sodium thiosulphate S.d.fine chemicals Ltd, Mumbai 
29 Sulphuric acid S.d.fine chemicals Ltd, Mumbai 
30 Thiobarbituric acid Rolex laboratory reagent, Mumbai 
31 Thionyl chloride S.d.fine chemicals Ltd, Mumbai 
32 Trichloro acetic acid Span diagnosis Ltd, Bangalore 
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6.4. PRELIMINARY PHYTOCHEMICAL ANALYSIS 169 
                   The Hydroalcoholic extract of Withania somnifera (HAREWS) was subjected to 
preliminary phytochemical screening for the presence or absence of phyto-constituents by the 
following methods.    
1.Test for alkaloids:  
The extract was treated with dilute hydrochloric acid and filtered. The filtrate is used in the 
following tests.   
a) Mayer’s reagent (Potassium Mercuric Iodine Solution)  
0.5ml of the extract was treated with Mayer’s reagent and the appearance of cream 
color indicates the presence of alkaloid 
b) Dragendroff’s test (Potassium Bismuth Iodide)  
0.5ml of the extract was treated with Dragen droff’s reagent and the appearance of 
reddish brown color precipitate indicates the presence of alkaloid.  
c) Hager’s test (Saturated solution of Picric acid)  
0.5ml of the extract was treated with Hager’s test and the appearance of yellow color 
precipitate indicates the presence of alkaloid.  
d) Wagner’s test (Iodine-Potassium Iodide Solution)  
0.5ml of the extract was treated with Wagner’s test and the appearance of brown color 
precipitate indicates the presence of alkaloid.   
 
 
 
 
Evaluation Of Hydro alcoholic Root Extract Of Withania somnifera Against Propionic Acid Induced 
Autism Spectrum Disorder In Mice 
 
Department of Pharmacology  
 Page 53 
 
 
2) Test for Carbohydrates   
a) Molisch’s test:  
The extract was treated with 3ml of alpha-napthol in alcohol and concentrated 
sulphuric acid was added along the sides of the test tube carefully. Formation of violet color 
ring at the junction of two liquids indicates the presence of carbohydrates.      
  b) Fehling’s test (CuSO4.7H2O+KOH+Potassium Tartarate): 
The extract was treated with Fehling’s solution A and B heated in boiling water for 
few minutes. The appearance of reddish brown color precipitate indicates the presence of 
reducing sugars.  
c) Benedict’s test (Sodium citrate + sodium carbonate + CuSO4.7H2O) 
The extract was treated with Benedict’s test and heated in boiling water for few 
minutes. The appearance of reddish orange color precipitate indicates the presence of 
reducing sugars.  
d) Barfoed’s test (Copper Acetate+ Glacial acetic acid) 
The extract was treated with Barfoed’s test and heated in boiling water for few 
minutes. The appearance of reddish orange color precipitate indicates the presence of non- 
reducing sugars.   
3) Test for steroids  
a) Libermann Burchard test:  
 The extract was treated with small quantity of concentrated sulphuric acid, glacial 
acetic acid and acetic anhydride. The appearance of green color indicates the presence of 
steroids   
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 4) Test for proteins  
a) Biuret’s test: 
The extract was treated with copper sulphate and sodium hydroxide solution. The 
appearance of violet color indicates the presence of proteins.  
b) Millon’s test: 
The extract was treated with Millon’s reagent. The appearance of pink color indicates 
the presence of proteins.  
5) Test for Tannin’s  
a) The extract was treated with 10% lead acetate solution. The appearance of white 
precipitate indicates the presence of tannins.  
b) The extract was treated with aqueous bromine solution. The appearance of white 
precipitate indicates the presence of tannins.   
6) Test for Phenols  
a) The extract was treated with neutral ferric chloride solution. The appearance of 
violet indicates the presence of phenols.  
b) The extract was treated with 10% sodium chloride solution. The appearance of 
cream color indicates the presence of phenols.  
7) Test for Flavonoid’s  
a) 5ml of extract solution was hydrolysed with 10%v/v sulphuric acid and cooled. 
Then, it is extracted with diethyl ether and divided into three portions in three separate test 
tubes. 1ml of diluted sodium carbonate, 1ml of 0.1N sodium hydroxide, and 1ml of strong 
ammonia solution were added to the first, second and third test tubes respectively. In each 
test tube, development of yellow color demonstrated the presence of flavonoids.  
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b) Shinoda’s test: The extracts were dissolved in alcohol, to that one piece of 
magnesium is added followed by concentrated hydrochloric acid along the sides of the test 
tube drop wise. It is heated in a boiling water bath for few minutes. The appearance of 
magenta colour indicates the presence of flavonoids.  
   8) Test for Gums and Mucilage 
The extract was treated with 25ml of absolute alcohol and then solution was filtered. 
The filtrate was examined for its swelling properties.      
9) Test for Glycosides 
The extract was dissolved in the glacial acetic acid and few drops of ferric chloride 
solution was added, followed by the addition of concentrated sulphuric acid, formation of red 
ring at the junction of two liquids indicates the presence of glycosides.   
 10) Test for Saponins               
           1ml of the extract was diluted to 20ml with distilled water and shaken well in a test 
tube. The formation of foam in the upper part of the test tube indicates the presence of 
saponins.   
11) Test for Terpenes   
The extract was treated with tin and thionyl chloride, appearance of pink color 
indicates the presence of terpenes.   
12) Test for sterols  
The extract was treated with 5% potassium hydroxide solution; appearance of pink 
color indicates the presence of sterols.   
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 6.5. ACUTE TOXICITY STUDIES 170 
                    The procedure was followed by using OECD 423 guidelines 423.The acute toxic 
class method (423) is a step wise procedure with 3 animals of single sex per step. Depending 
on the mortality and/or morbidity status of the animals, on the average 2-4 steps may be 
necessary to allow judgment on the acute toxicity of the substances. This procedure results in 
the use of a specified number of animals while allowing for acceptable data- based scientific 
conclusion.   
     The method used defined doses (2000mg/kg body weight) and results allow a substance to 
be ranked and classified according to the Globally Harmonized System (GHS) for 
classification of chemical which cause acute toxicity.  
Procedure:  
Adult female Swiss albino mice 25- 35gms were used for the study. The starting dose 
level of Hydro-alcoholic root extract of Withania somnifera (HAREWS) was 2000mg/kg 
body weight p.o. as most of the crude extracts possess LD50 value more than 2000 mg/kg, 
p.o. so starting dose used was 2000mg/g p.o. Dose volume administered was 1ml/100 gm 
body weight to mice which were fasted overnight with water ad libitum. Food was withheld 
for further 3-4hrs after oral administration of drugs and observed for the signs of toxicity.    
Body weight of mice’s before and after determination were noted and any changes in 
skin and fur, eyes and mucous membrane, respiratory, circulatory, autonomic & central 
nervous system, motor activity and behavior pattern were observed and also sign of tremors, 
convulsion, salivation, diarrhoea, lethargy, sleep and coma were noted. The onset of toxicity 
and signs of toxicity also noted. 
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6.6. EXPERIMENTAL DESIGN 
Swiss albino male mice were obtained at age 26 days from the animal house of 
C.L.Baid Metha College of Pharmacy, Thoraipakkam, Chennai- 97, and housed in groups of 
six at 22±2◦C in acrylic cages (26cm×48cm×21 cm) for 7 days for acclimation to the animal 
colony, with 12hrs light/dark cycle and access to pellet chow and water ad libitum. Post-
surgical housing was individual for 7 days to allow recovery.Ethical committee clearance was 
obtained from IAEC (Institutional Animal Ethics Committee) of CPCSEA (Committee for 
the Purpose of Control and Supervision of Experiments on Animals).   
IAEC Reference: IAEC/XLVII03/CLBMC P/2015 
After recovery of mice (41±4days old), the animals were assigned as follows: 
GROUP TREATMENT DURATION 
Group I – Normal control Normal saline, p.o For 28 days 
Group II – Negative control Propionic acid (1µl of 0.26M 
solution), icv. 
For 7 days (2dose/day); 
From 22nd to 28th day 
Group III – Low dose HAREWS (200mg/kg), p.o For 28 days 
Group IV – High dose HAREWS (400mg/kg), p.o For 28 days 
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6.7. INDUCTION OF ASD 
 Cannula implantation 171, 172 
For surgery a mouse was anaesthetized with 4% isoflurane and 2 L/min oxygen and 
placed in a standard stereotaxic device, with maintenance of anaesthesia. The cannula, a 30- 
gauge needle, at angle at 9° was implanted 3mm deep, into the left ventricle with the 
following co-ordinates with reference to bregma: midline, anterior/posterior -0.3mm, 
medial/lateral 1.3mm. Four small stainless steel screws were inserted into the skull 
surrounding the cannula to provide anchors for dental acrylic, which attached the cannula to 
the skull. The gauge injection cannula was connected to a Sage syringe pump by PE10 
tubing.  A removable plug sealed the guide cannula until an injection was to be made. 
Immediately after post-surgery, all mice received a subcutaneous injection of analgesic 
(pentazocine, 10mg/kg). 
 ICV infusion of propionic acid (PPA) 171 
All groups except normal control received intracerebro ventricular (icv) infusions 
twice daily, separated by 4 h, for seven consecutive days. Behavioural test sessions were 
carried out immediately after icv infusion of 1µl of 0.26M propionic acid (Solutions were 
buffered to physiological pH 7.5 before injection using hydrochloric acid or sodium 
hydroxide.). Each injection consisted of 1µl of solution delivered over a period of 1min. To 
ensure that the entire injection had been delivered, the injection cannula was allowed to 
remain in place for an additional minute before being removed. The behavioural test sessions 
were separated by a 1 week recovery period 
  All mice were used in all behavioural tests, with PPA administered 
shortly before each test except to the normal control group. Test sessions were separated by 
intervals of 24 or 48 h, as indicated below, because of an active period of PPA in brain for 
producing behavioural and brain electrographic changes lasting no more than 40–60 min. 
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6.8. ASSESSMENT OF HABITUATION BEHAVIOUR 
1.Locomotor, repetitive/stereotypic behavior 173  
                The locomotor activity of mice is recorded individually for each animal in an 
actophotometer. It was recorded on 22nd and 26th day of experiment. It is equipped with 3 
infrared emitters located on the x- and y- axis, and with an equivalent number of receivers on 
the opposite walls of the cage. The behavior of mice was analyzed. The locomotor activity 
was defined as a breakage of three consecutive photo- beams. The time of 
repetitive/stereotypic- like activity was defined as the sum of time intervals (1/10th of a 
second) in which there was a movement, but an animal did not cross three consecutive photo-
beams. The animal would have to repeatedly break and make the same three beams for the 
time interval (1/10th of a second) to be recorded as time of repetitive/stereotypic-like activity. 
The number of repetitive/stereotypic-like movements was defined as the number of repeated 
breaks of the same beam in 1/10th of a second. 
2.Nociception threshold 173.174  
 
             Nociceptive effects were evaluated on 22nd and 27th day using tail flick. The 
tail flick test is to be carried out by restraining the animal by hand, and its tail was immersed 
≈2 cm into water heated to 50±5°C. After tail immersion, the time at which tail flick response 
was noted was recorded. The cutoff time is 15s. Tail flick measurements are taken three times 
at 30s intervals to obtain average pain threshold of mice. 
  3. Object-directed behavior13 
         The novel objects, three different small toys were placed equidistant from each 
other approximately 10cm from the wall of the open-ﬁeld arena. After administration of the 
assigned treatment on 23rd and 25th day, the mouse was placed at the center of the arena and 
allowed to explore and interact with the objects for 5min. Each mouse should be tested once 
and the same 3 objects are used for all tests, counterbalanced for position within groups. A 
20cm-diameter zone around each object is defined and the percentage approach into, and total 
duration(s) in each zone is determined. Sniffing bouts at each object by each mouse is 
recorded. A sniffing bout was scored when a mouse approached an object with its snout 
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placed within 1cm of the object and with the vibrissae moving to indicate sniffing, and ended 
when the snout is withdrawn farther than 1cm from the object. 
 4. Novel mice vs. novel object-directed behavior 136 
 This test is carried out 24h or 48hrs after the object-directed behavior test and 
evaluated social for behavior. The test was carried out on 24th and 27th day. A novel male 
mouse of the same body weight as the subject mouse, and an object not used in the previous 
object-directed behavior test, are placed opposite each other in the arena approximately 10cm 
from the wall of the arena. The novel mouse movements are restricted by placing it in the 
small wire mesh cage. 
 The subject mouse is placed at the center of the arena midway between the novel 
object and the novel mouse facing the bare wall of the arena, and allowed to explore for 
5min. Mice are tested one at a time, and the arena and object were cleaned with an alcohol–
water solution after each mouse is tested. Each mouse is tested once and the same object was 
used for all tests, with stimulus object/mice positions counterbalanced within groups. Percent 
of time approaching the novel mouse 1) the novel object 2) by the subject mouse is 
calculated.  
  5. Elevated Plus Maze 175 
 On 28th day, all mice were subjected to elevate plus maze for 5min to assess anxiety 
level. Maze is composed of 2 open arms (16x5cm) and 2 closed arms (16x5x12cm) with open 
roof top. The maze is elevated at the height of 25cm. Each animal was placed at the center of 
the maze facing towards open arm. The following parameters are recorded: (a) transfer 
latency to enter open arm, (b) time spent in open arm, (c) number of entries into open arm in 
5min of the session. 
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6.9. ASSESSMENT OF MEMORY AND RETENTION 
Morris water maze 176,177 
       The Morris water maze method is performed to evaluate spatial working and 
reference memory. The experimental apparatus consists of a circular tank (120 cm in 
diameter, 45 cm in height). An invisible platform (15 cm in diameter, 35 cm height) was 
placed 1.5 cm below the surface of the water. Water was kept opaque by dissolving small 
quantity of milk at a temperature of 21-23ºc. The pool was located in a test room and many 
cues external to the maze were visible from the pool, which could be used by the mice for 
spatial orientation. The position of the cues was kept constant through the task. The training 
trials were carried out from 26th to 28th day- 4 trials per day. The platform is located in a 
constant position throughout the test period in the middle of one quadrant, equidistant from 
the center and edge of the pool. In each training session, the latency to escape to the hidden 
platform was recorded. 
    On 28th day, the platform was removed and the animals were tested for its memory 
where the time spent by each animal in target quadrant searching for the hidden platform is 
noted as an index of retrieval. 
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6.10. ESTIMATION OF BRAIN NEUROTRANSMITTER 
Estimation of serotonin 178 
Reagents: 
1. HCl- Butanol sol: (0.85ml of 37% hydrochloric acid in one-liter n-butanol) 
2.Heptanes 
3.0.1 M HCl : (0.85ml of conc. HCl upto 100ml H2O) 
4. O-phthaldialdehyde (OPT) reagent (20mg in 100ml conc. HCl) 
Procedure 
On the 28th day of experiment, immediately after MWM, mice were sacrificed, whole 
brain was dissected out and the sub cortical region (including the striatum) was separated.  
Weight tissue was weight and was homogenized in 5ml HCl- butanol for about 1 min. The 
sample was then centrifuged for 10 min at 2000 rpm.  An aliquot supernatant phase (1 ml) 
was removed and added to centrifuge tube containing 2.5 ml heptanes and 0.31 ml HCl of 
0.1M.  After 1min of vigorous shaking, the tube was centrifuged under the same conditions 
above in order to separate the phases, and the overlaying organic phase was discarded.  The 
aqueous phase (0.2ml) was then taken for 5HT assay.  All steps were carried out at 00C.  
(N.B: it taken in between 50-75mg of tissue for homogenate with 5ml of HCl-butanol in 
correlation of same tissue concentration 1.5-5mg/0.1ml of HCl-butanol used in Schlumpf M 
et al, 1974.  This is done to get adequate amount of supernatant liquid for analysis) 
  To 0.2ml aqueous extract, 0.25ml of OPT reagent was added. The fluorophore 
was developed by heating to 100°C for 10min. After the samples reached equilibrium with 
the ambient temperature, readings were taken at 360-470nm in the spectrofluorimeter. Tissue 
blank, 0.25ml conc. HCl without OPT was added. Internal standard: 500µg/ml was prepared 
in distilled water: HCl-butanol in 1:2 ratio. 
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 6.11. Estimation of Neuroinflammation 
Estimation of cytokine: TNFα 179 
Reagents 
1.50mM Tris (pH 7.2) 
2.1mM EDTA 
3.6mM MgCl2 
4.5% protease inhibitor cocktail 
Procedure 
        Brain tissue was homogenized in 1ml ice cold buffer (pH 7.2, 4o C) having 50 mM Tris, 
1mM EDTA, 6mM MgCl2, 5%(w/v) protease inhibitor cocktail. Then samples were sonicated 
and centrifuged at 20, 800g for 20 min in cooling centrifuge. The supernatants were used for 
the determination of TNF-α using commercially available ELISA kit obtained from Ray 
Biotech, USA. The procedures were followed as per the manufacturer’s instructions. All data 
are expressed as pg/ml. 
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Estimation of cytokine: Interleukin 6 (IL-6) 180 
  Reagents 
1. RIPA buffer (50mM Tris-Hcl,150mM Nacl pH-7.4) 
2.1mM EDTA 
3.1mM PMSF 
4.Protease inhibitor cocktail. 
  Procedure  
     One half of the brain tissue was homogenized using disposable rotor 
homogenizer in 10 volumes of RIPA (radio-immune precipitation assay ) buffer (50mM Tris 
–Hcl, 150mM Nacl, pH 7.4) supplemented with 1mM EDTA, 1mM PMSF(phenyl methyl 
sulpfonyl fluoride) and protease cocktail was separated to sub cellular fraction..The 
homogenate centrifused at 29000g  for 20min. The pellet was resuspended with RIPA buffer 
containing 1mM EDTA and protease cocktail, whilst the supernatant was centrifuged at 
29000 for 45min.the supernatants was used for the determination of IL-6 by specific 
quantitative sandwich ELISA kits according to the manufacturer’s instruction. 
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6.12. ESTIMATION OF ANTIOXIDANT ENZYMES 
Estimation of Superoxide dismutase (SOD) 181 
Reagents 
1. Carbonate buffer (100mM, pH 10.2) 
2. Epinephrine (3mM) 
Procedure 
  The SOD activity in supernatant was measured by the method of Misra and 
Fridovich. The supernatant (500µl) was added to 0.800ml of carbonate buffer (100mM, pH 
10.2) and 100µl of epinephrine (3mM). The change in absorbance of each sample was then 
recorded at 480nm in spectrophotometer for 2min at an interval of 15sec. Parallel blank and 
standard were run for determination of SOD activity. 
One unit of SOD is defined as the amount of enzyme required to produce 50% 
inhibition of epinephrine auto oxidation. 
Reagents 
Uninhibited 
(Standard) 
Inhibited 
(Sample) 
Blank 
Carbonate 
buffer 
0.900ml 0.800ml 1.0ml 
Supernatant - 0.1ml - 
Epinephrine 0.1ml 0.1ml - 
 
The reaction mixtures are diluted 1/10 just before taking the readings in spectrophotometer 
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Calculation  
 
%𝐈ܖܐܑ܊ܑܜܑܗܖ =  ∆Aସ8଴୬୫ min⁄ Uninhibited − ∆Aସ8଴୬୫ min⁄ inhibited∆Aସ8଴୬୫ min⁄ Uninhibited − ∆Aସ8଴୬୫ min⁄  Blank × ͳͲͲ 
 
𝐔ܖܑܜܛ ܕܔ⁄ ܍ܖܢܡܕ܍ = %Inhibition × V୲ሺͷͲ%ሻ × Vୱ  
 𝐔ܖܑܜܛ ⁄ ܕ܏ܘܚܗܜ܍ܑܖ =  Units  ml enzyme⁄mg protein ⁄ ml enzyme 
Where, 
Vt = Total volume (1.0ml) 
Vs = Sample volume (0.1ml) 
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Estimation of Catalase (CAT) 182 
Reagents 
1.Phosphate buffer solution (50mM) 
i. Dissolve 6.81g of KH2PO4 in 1000ml distilled water 
ii. Dissolve 6.9g of Na2HPO4 in 1000ml distilled water 
390ml from solution (A) are mixed with 610ml from solution (B), the pH is adjusted 
to 7 
2.Hydrogen peroxide (H2O2) 30mM 
0.34ml of 30% H2O2 is diluted with phosphate buffer to 100ml 
Procedure 
  Catalase activity was measured by the method of Aebi. 0.1ml of supernatant was 
added to cuvette containing 1.9ml of 50mM phosphate buffer (pH 7.0). Reaction was started 
by the addition of 1.0ml of freshly prepared 30mM H2O2. The rate of decomposition of H2O2 
was measured spectrophotometrically from changes in absorbance at 240nm. Activity of 
catalase was expressed as units/mg protein. A unit is defined as the velocity constant per 
second.  
Reagents Sample Blank 
Phosphate buffer 1.9ml 2.9ml 
Supernatant 0.1ml 0.1ml 
H2O2 1ml - 
 
                The reaction occurs immediately after the addition of H2O2. 
 
Solutions are mixed well and the first absorbance (A1) is read after 15sec (t1) and the 
second absorbance (A1) after 30sec (t1). The absorbance is read at wavelength 240nm.  
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Calculation 
𝐊 =    V୲Vୱ × ʹ.͵∆t × log AଵAଶ ×  ͸Ͳ 
Where,  
K =Rate constant of the reaction 
∆t = (t2-t1) = 15sec 
A1 = Absorbance after 15sec 
A2 = Absorbance after 30sec 
Vt = Total volume (3ml) 
Vs = Volume of the sample (0.1ml) 
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Estimation of Lipid peroxidase (LPO) 183 
 The level of Lipid peroxidase was estimated by Thiobarbituric acid reaction method 
described by Ohkawa et al. 
Reagents 
1. Sodium dodecyl sulphate (SDS) (8.1% w/v) 
2. Acetic acid (20%; pH 3.5) 
3. Thiobarbituric acid (TBA) (0.8%) 
4. n-butanol/pyridine mixture (15:1) 
Procedure 
 To 0.2ml of test sample, 0.2ml of SDS, 1.5ml of acetic acid and 1.5ml of TBA were 
added. The mixture was made up to 4ml with water and then heated in a water bath at 95°C 
for 60min. After cooling, 1ml of water and 5ml of n-butanol/pyridine mixture were added and 
shaken vigorously. After centrifugation at 4000rpm for 10min, the organic layer was taken 
and its absorbance was read at 532nm. The level of lipid peroxides was expressed as nmoles 
of MDA released/g wet tissue. 
 
 
 
Reagents Sample Blank 
SDS 0.2ml 0.2ml 
Supernatant 0.2ml - 
DDW 1.6ml 1.8ml 
Acetic acid 1.5ml 1.5ml 
TBA 1.5ml 1.5ml 
n-
butanol/pyridine  
5ml 5ml 
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Calculation 
۱ܗܖ܋܍ܖܜܚ܉ܜܑܗܖ ܗ܎ 𝐌۲𝐀 =  Absorbance at ͷ͵ʹnmL × Є × D 
 Where,  
L = Light path (1cm) 
Є = Extinction co-efficient 1.56x105 M-1cm-1 
D =  Total volume ሺͳͲmlሻVolume of the sample ሺͲ.ʹmlሻ 
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Estimation of Glutathione Peroxidase 184 
Reagents 
1. Phosphate buffer, pH 7.0 (75mM) 
2. Glutathione reductase (60mM) 
3. Sodium azide (0.12M) 
4. Disodium EDTA (0.15mM) 
5. NADPH (3mM) 
6. H2O2 (7.5mM) 
Procedure 
3ml cuvette containing 2.0ml of phosphate buffer (75mmol/L, pH 7.0), 50µl of 
glutathione reductase (60mmol/L), 50µl of NaN3 (0.12mol/L), 0.1ml of Na2EDTA 
(0.15mM/L), 100µl of NADPH (3.0mmol/L) and tissue supernatant were added. Water was 
added to make a total volume of 2.9ml. The reaction was started by the addition of 100µl of 
(7.5mmol/L) H2O2, and the conversion of NADPH to NADP was monitored by a continuous 
recording of the change of absorbance at 340nm at 1min interval for 5min. Enzyme activity 
of GSHPx was expressed in terms of mg of protein. 
Reagents Sample Blank 
Phosphate buffer 2.0ml 2.9ml 
Glutathione 
reductase 
0.05ml 0.05ml 
Sodium azide 0.05ml 0.05ml 
Disodium EDTA 0.1ml 0.1ml 
NADPH 0.1ml 0.1ml 
Supernatant 0.1ml 0.1ml 
H2O2 0.1ml - 
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DDW 0.5ml 0.6ml 
Calculation 
۳ܖܢܡܕ܍ ܉܋ܜܑ𝐯ܑܜܡሺ𝐌 ܕܑܖ⁄ ܕܔ⁄ ሻ =  Aଷସ଴ ∕ min× V୲ε × d × Vୱ  
Where,  
ε = 6.22 x 106 M-1cm-1 
d = 1cm 
Vt = Total volume (3.0ml) 
Vs = Sample volume (0.1ml) 
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Estimation of Glutathione Reductase (GRD) 185 
Glutathione reductase was assayed by the method of Stahl et al. 
Reagents 
1. Phosphate buffer (0.3M; pH 6.5) 
2. EDTA (0.25M) 
3. Glutathione oxidized, GSSG (0.012M) 
4. NADPH (0.03M); Nicotinamide Adenine Dinucleotide Phosphate reduced tetra 
sodium salt, NADPH.Na4 (Mw.833.35) 
Procsedure  
 The reaction mixture containing 1ml phosphate buffer, 0.5ml EDTA, 0.5ml GSSG and 
0.2ml of NADPH was made up to 3ml with distilled water. After the addition of 0.1ml of 
tissue homogenate, the change in optical density at 340nm was monitored for 2min at 30sec 
interval. 
 One unit of the enzyme activity was expressed as nmoles of NADPH 
oxidized/min/mg protein. 
Reagents Sample Blank 
Phosphate buffer 1.0ml 1.5ml 
EDTA 0.5ml 0.5ml 
GSSG 0.5ml - 
NADPH 0.2ml 0.2ml 
Supernatant 0.1ml 0.1ml 
DDW 0.8ml 0.8ml 
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Calculation 
۳ܖܢܡܕ܍ ܉܋ܜܑ𝐯ܑܜܡሺ𝐌 ܕܑܖ⁄ ܕܔ⁄ ሻ =  Aଷସ଴ ∕ min× V୲ε × d × Vୱ  
Where,  
ε = 6.22 x 106 M-1cm-1 
d = 1cm 
Vt = Total volume (3.1ml) 
Vs = Sample volume (0.1ml) 
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6.13. Methods for Histopathological study  
The mice from each group were anaesthetized using intraperitoneal injection of 
sodium pentobarbital (50mg/kg).  The brain was carefully removed without injury after 
opening the skull. The collected brain was washed with ice cold normal saline and fixed in 
10% formal saline (10ml of formaldehyde in 90ml of physiological saline). Paraffin 
embedded sections were taken 100𝜇m thickness and processed in alcohol-xyline series and 
stained with haematoxylin-eosin dye. The sections were examined microscopically for 
histopathological changes. 
6.14. Statistical Analysis 
The statistical analysis was carried by one way ANOVA followed by Dunnet’s “t” 
test.  P value <0.05 (95% confidence limit) was considered statistically significant, using 
software Graph Pad Prism version6.  
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RESULTS:  
 7.1 Extraction yield  
              The hydro-alcoholic root of Withania somnifera dried extract was dark chocolate 
brown in colors and was stored in refrigerator until use. The percentage yield of the extract 
was 15.02% w/w. 
7.2 Preliminary Phytochemical study:  
          The hydro-alcoholic root extract of Withania somnifera showed presence of various 
Phyto-chemical constituents such as  alkaloids, carbohydrate, proteins, tannins, steroids,  
glycosides, flavonoids, and saponins.  Results are shown in Table 1 
7.3. Acute Toxicity study:   
        According to the OECD guideline 423 (Acute toxic class method) acute oral toxicity 
studies were performed. A single starting dose of 2000mg/kg p.o was administered to the 
animal and observed for three days. There was no significant change in body weight of the 
animals before and after treatment of drug and no signs of toxicity was found and the animals 
were observed for 14 days. No signs of toxicity were found. Results are shown in Table 2. 
  7.4. Assessment of Habituation behavior:  
 Effect of HAREWS on Locomotor, repetitive/stereotypic behavior:  
        The Group II animals showed a significant decrease in locomotor activity compared to 
the Group I animals. Treatment with HAREWS (200&400 mg/kg) significantly increased the 
locomotor activity (Group III & Group IV) on comparison with Group II. There was 
significant difference in the repetitive / stereotypic behavior of both Group I and Group II 
animals. Treatment with HAREWS (200& 400mg/kg) significantly decreased the number 
and duration of repetitive / stereotypic activity. Results are given in Table4 and represent 
Graph2 
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 Effect of HAREWS on Nociception thresholds: 
    The Group II animal shows increase in nociception threshold when compared with the 
Group I. Treatment with HAREWS (200&400mg/kg) significantly decreased the nociception 
threshold when compared with the Group II. Results are shown in Table5 and represent 
Graph 3 
 Effect of HAREWS on object directed behavior 
           There was a significant increase in object directed activity by Group II when compared 
with Group I and significant decrease when compared with Group III and IV.  Treatment with 
HAREWS (200mg/kg &400mg/kg) object directed behavior significantly decreased. 
Percentage object directed behavior, number of sniffing bouts and their spent time in each 
zone is given in Table 6, 7, 8 respectively and Graph 4, 5, 6. 
 Effect of HAREWS on social directed behavior 
There was a significant decrease in percentage approach towards novel mice by 
Group II when compared with Group I. Treatment with HAREWS (200mg/kg &400mg/kg) 
showed significant increase in percentage approach to novel mice on comparison with Group 
II. Results are given in Table 9 and represent in Graph 7. 
Effect of HAREWS on elevated plus maze 
There was no significant difference between Group II & Group I,   Group III & Group 
IV in number of entries, time spent and transfer latency to open arm. But Group I showed 
significant difference on time spent in open arm when compared with Group II. Results are 
given in Table 10 and represented in Graph 8, 9. 
7.5 Assessment of memory and retention 
 Effect of HAREWS of Morris water maze test: 
The Group II animal showed increase in latency period on comparison with Group I 
animals. Treatment with HAREWS 200mg/kg & 400mg /kg decreased the latency time 
significantly (Group III and Group IV) on comparison with the Group II. Results are given in 
Table 11 and represented in Graph 10 
Evaluation Of Hydro alcoholic Root Extract Of Withania somnifera Against Propionic Acid Induced 
Autism Spectrum Disorder In Mice 
 
Department of Pharmacology  
 Page 78 
 
 
7.6. Estimation of Neurotransmitter 
Effect of HAREWS on Serotonin 
The serotonin level in the brain of Group II animals was increased significantly on 
comparison with Group I animals. All treatment groups treated with HAREWS 200mg/kg & 
400mg/kg (Group III & Group IV respectively) exhibited significant decrease in the level of 
serotonin in comparison with Group II animals. Results are given in Table 12 & represented 
in Graph11.   
7.7. Estimation of Neuroinflammation: 
Effect of HAREWS on TNF-α 
         The brain TNF-α level of Group II animals were increased significantly on comparison 
with Group I animals. All treatment groups treated with HAREWS200mg/kg & 400mg/kg 
(Group III & Group IV respectively) exhibited significant decrease in the level of TNF-α in 
comparison with Group II animals. Results are given in Table 13 & represented in Graph 
12. 
Effect of HAREWS on Interleukin 6 (IL-6) 
      The IL-6 level in the brain of Group II animals was significantly increased on 
comparison with the Group I animals. All treatment Groups treated with HAREWS 
200mg/kg & 400mg/kg (Group III& Group IV) showed significant decrease in the level of 
IL-6 in comparison with Group II animals. Results are given in Table14 & represented in 
Graph 13. 
7.8. Estimation of Antioxidant Enzymes 
Effect of HAREWS on Superoxide dismutase 
  SOD level in the brain of Group II animals was decreased significantly on 
comparison with Group I animals. Treatment with HAREWS 200mg/kg and 400mg/kg 
(group III & Group IV) showed significant increase in SOD level on comparison with Group 
II animals. Results are given in Table15 and Graph14. 
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Effect of HAREWS on Catalase 
    Catalase level in the brain of Group II animals were found decreased significantly 
on comparison with Group I animals. Treatment with HAREWS 200 and 400mg/kg (Group 
III & Group IV) showed significant increase in catalase level on comparison with Group II 
animals. Results are given in Table16 and represented in Graph 15. 
 Effect of HAREWS on Lipid peroxidation 
     Lipid peroxidation in the brain of Group II animal were found increased 
significantly on comparison with HAREWS 200& 400mg/kg (Group III & Group IV) 
showed significant decrease in lipid peroxidation on comparison with Group II animals. 
Results are given in Table17 and represented in Graph 16 
Effect of HAREWS on Glutathione peroxidase 
    Glutathione peroxidase in the brain of Group II animals were found decreased 
significantly on comparison with Group I animals. Treatment with HAREWS 200 mg/kg & 
400mg/kg (Group III & Group IV) showed significant increase in Glutathione peroxidase 
level on comparison with Group II animals. Results are given in Table18 & represented in 
Graph 17 
 Effect of HAREWS on Glutathione reductase 
          Glutathione reductase in the brain of Group II animals were found decreased 
significantly on comparison with Group I animals. Treatment with HAREWS 200 & 
400mg/kg (Group III & Group IV) showed significant increase in Glutathione reductase level 
on comparison with Group II animals. Results are given in Table 19 & represented in Graph 
18 
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7.8. Tables & Graphs: 
                          
Table 2:  Preliminary Phytochemical study 
 
 
       Sl.No              Constituents                      Remarks  
1 Alkaloids Present  
2 Carbohydrates Present 
3 Proteins Present 
4 Steroids Present 
5 Phenols Absent 
6 Tannins Present 
7 Glycosides Present 
8 Flavonoids                        Present 
9 Saponins 
 
Present 
10 Terpens  Absent  
11            Gum & Mucilage Absent 
12 Sterols Absent 
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  Table 3: Acute oral toxicity results of HAREWS 
 
 
 
 
 
 
Sl 
N
o 
 
 
 
Treatmen
t 
 
 
 
Dose 
 
Weight of 
animals 
 
 
Sign of 
toxicit
y 
 
Onset 
of 
toxicit
y 
 
Reversible  
or 
Irreversibl
e 
 
 
Duratio
n  
 
Befor
e 
 
Afte
r  
 
 
 
1 
 
 
 
 
 
HAREWS 
 
 
 
 
 
2000mg/k
g 
 
 
 
 
 
30 
 
 
 
 
 
32 
 
 
 
 
 
 
 
 
 
 
No 
sign of 
toxicity 
 
 
 
 
 
 
 
 
 
Nill 
 
 
 
 
 
 
 
 
 
Nill 
 
 
 
 
 
 
 
 
 
14 days 
 
 
 
2 
 
 
 
 
 
 
HAREWS 
 
 
 
 
 
 
 
2000mg/k
g 
 
 
 
 
 
 
25 
 
 
 
 
 
 
28 
 
 
 
 
 
3 
 
 
 
 
HAREWS 
 
 
 
 
2000mg/k
g 
 
 
 
 
30 
 
 
 
 
35 
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                 Table 4: Effect of HAREWS on Locomotor, repetitive/ stereotypic activity  
 
 
Sl
.n
o 
 
 
 
Treatment  
 
 
Locomotory 
activity Scores 
 
 
No. of 
repetitive/stereotyp
ic activity 
 
 
Duration of 
repetitive/stereotyp
ic activity 
1 Normal saline 295.00±4.55         0.00         0.00 
2 Negative 
control(PPA) 
167.00±3.87a*** 168.00±6.08a*** 80.33±2.30a*** 
3 HAREWS200mg/kg  234.00±6.10b*** 48.83±2.81b*** 18.50±0.67b*** 
4 HAREWS400mg/kg   264.30±7.77 ns 33.17±1.62b*** 9.16±0.83b*** 
 
                 Values are represented in Mean ± SEM, n=6 
                 Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
 Statistical significance test for comparison was done by one way ANOVA followed 
by Dunnet’s‘t’ test   
   ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
             Graph 2: Effect of HAREWS on Locomotor, repetitive / stereotypic activity  
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                         Table 5: Effect of HAREWS on Nociception thresholds 
 
 
Sl.no 
 
Treatment 
 
Nociception thresholds 
 
 
1 
 
Normal saline 
 
4.50±0.42 
 
2 
 
Negative control(PPA) 
 
6.33±0.84 ns 
 
3 
 
HAREWS200mg/kg 
 
2.83±0.30b*** 
 
4 
 
HAREWS 400mg/kg 
 
2.50± 0.42b*** 
 
 
              Values are represented in Mean ± SEM, n=6 
              Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
 Statistical significance test for comparison was done by one way ANOVA followed 
by Dunnet’s‘t’ test            
                ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
                         Graph3: Effect of HAREWS on Nociception thresholds 
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 Table 6:  Effect of HAREWS on object-directed behavior: percentage approach 
 
 
  
                    Values are represented in Mean ± SEM, n=6 
                 Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
  Statistical significance test for comparison was done by one way ANOVA 
followed by Dunnet’s‘t’ test 
                   ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
 
                        Graph 4: Effect of HAREWS on object –directed behavior 
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Sl.no 
 
 
Treatment 
% approach towards object 
A B C 
1 Normal saline 44.00±2.22 26.50±2.79 29.67±2.04 
2 Negative control 
(PPA) 
54.17±1.17a** 15.17±2.00a** 13.17±1.01a*** 
3 HAREWS 200mg/kg 34.33±1.35b**** 21.33±1.33ns 20.50±1.33b*** 
4 HAREWS  400mg/kg 43.00±1.59b*** 26.83±1.35b** 24.33±1.20b**** 
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Table 7:  Effect of HAREWS on Object-directed behavior: Number of sniffing bouts 
 
 
  Sl. No  
 
 
       Treatment  
 
                 Number of sniffing bouts  
            A 
 
             B C 
1 Normal saline   10.33±0.67 8.33±0.55 8.50±0.42 
2 Negative control (PPA) 5.55±0.67a*** 3.66±0.21a*** 4.33±0.30a*** 
3 HAREWS200mg/kg 7.50±0.56b*** 5.66±0.33b*** 5.16±0.60ns 
4 HAREWS 400mg/kg 9.56±0.47b*** 6.83±0.47b*** 7.50±0.42b*** 
 
 
              Values are represented in Mean ± SEM, n=6 
               Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
 Statistical significance test for comparison was done by one way ANOVA followed 
by Dunnet’s‘t’ test          
                  ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
 
 
                      Graph5: Effect of HAREWS on No. sniffing bouts 
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 Table 8: Effect of HAREWS on object directed behavior: Time spent on objects 
 
 
             Values are represented in Mean ± SEM, n=6 
             Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
Statistical significance test for comparison was done by one way ANOVA followed 
by Dunnet’s‘t’ test 
     
            ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
Graph 6: Effect of HAREWS on object –directed behavior: Time spent on objects                                       
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  Sl.No 
 
 
       Treatment  
       
              Time spent on objects (sec) 
 
A 
 
B 
 
C 
 
1 
 
Normal saline 
 
144.20±5.97 
 
  65.57 ±1.52 
  
   59.67  ±1.54 
 
2 
 
Negative control 
(PPA) 
 
105.70±2.71a*** 
 
100.70±1.52a*** 
 
 73.83  ±1.04a*** 
 
 
 
3 
 
HAREWS 200mg/kg 
 
 125.00 ±1.50ns 
 
              
   90.50±1.33b*** 
         
   79.50  ±0.99ns 
 
4 
 
HAREWS 400mg/kg 
  
105.00 ±2.63b** 
 
80.50±1.43b*** 
    
87.83±2.25b*** 
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  Table 9: Effect of HAREWS on Social behavior  
 
 
    
                 Values are represented in Mean ± SEM, n=6 
                 Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
    Statistical significance test for comparison was done by one way ANOVA followed 
by             Dunnet’s‘t’ test 
                ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
 
                        Graph 7: effect of HAREWS on Social behavior  
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Sl.No.  
 
      Treatment  
                                    % approach 
                Novel Mice             Novel Object  
1 Normal saline              55.33±3.50              33.50±2.43 
2 Negative control(PPA)              31.77±2.05a***              58.17±2.07a*** 
3 HAREWS200mg/kg              58.83±2.41b***             30.50±1.62b*** 
4 HAREWS400mg/kg             63.17±2.18b***             27.50±1.83b*** 
Evaluation Of Hydro alcoholic Root Extract Of Withania somnifera Against Propionic Acid Induced 
Autism Spectrum Disorder In Mice 
 
Department of Pharmacology  
 Page 88 
 
 
                               Table10: Effect of HAREWS on Elevated Plus Maze 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  
 
 
       Sl no  
      
       Treatment  
 
No of entries  
 
Transfer  
latency  
 
Time spent  
 
          1 
 
Normal saline 
 
4.00±0.57 
 
36.83±10.73 
 
88.33±15.15 
 
          2 
 
Negative control    
(PPA)  
 
4.00±1.00ns 
 
45.00±11.71ns 
 
 
43.33±12.51ns 
 
          3 
 
HAREWS200mg/kg 
 
4.50±1.05ns 
 
34.00±8.98ns 
 
81.55±12.17ns 
 
          4 
 
HAREWS400mg/kg 
 
4.50±1.02ns 
 
58.00±15.43ns 
 
83.17±11.63ns 
 
 
Values are represented in Mean ± SEM, n=6 
Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
Statistical significance test for comparison was done by one way ANOVA followed by Dunnet’s‘t’ 
test 
  ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
           Graph 8:  Effect of HAREWS on No of Entries in open arms  
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  Graph 9:     Effect of HAREWS on Transfer latency & time spent 
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                            Table 11: Effect of HAREWS on Morris water test 
 
 
 
              Values are represented in Mean ± SEM, n=6 
              Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
  Statistical significance test for comparison was done by one way ANOVA 
followed by Dunnet’s‘t’ test.        
               ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
                           Graph10: Effect of HAREWS on Morris water test 
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Sl.no 
 
Treatment 
 
Escape Latency( sec) 
 
1 
 
Normal saline 
 
15.8±2.3 
 
2 
 
Negative control(PPA) 
 
59.3±7.3a*** 
 
3 
 
HAREWS 200mg/kg 
 
16.0±2.6b*** 
 
4 
 
HAREWS 400mg/kg 
 
13.0±1.6b *** 
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                              Table12: Effect of HAREWS on Serotonin 
 
 
Sl.no 
 
Treatment 
 
Serotonin (ng/mg tissue) 
 
1 
 
Normal saline 
 
12.67±  2.17 
 
2 
 
Negative control (PPA) 
 
49.33±8.65a*** 
 
3 
 
HAREWS 200mg/kg 
 
19.83±2.73b** 
 
4 
 
HAREWS 400mg/kg 
 
13.50±1.72b** 
 
         
            Values are represented in Mean ± SEM, n=6 
            Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
    Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s‘t’ test 
            ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
 
                                  Graph11: Effect of HAREWS on Serotonin  
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                                   Table13: Effect of HAREWS on TNF-α 
 
 
Sl.no 
 
Treatment 
 
TNF-α (pg/ml) 
 
1 
 
Normal saline 
 
2.5  ±  0.77 
 
2 
 
Negative control (PPA) 
 
3.15±0.08a*** 
 
3 
 
HAREWS 200mg/kg 
 
1.41±0.011b*** 
 
4 
 
HAREWS 400mg/kg 
 
1.77±0.031b*** 
 
 
              Values are represented in Mean ± SEM, n=6 
Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
   Statistical significance test for comparison was done by one way ANOVA followed 
by Dunnet’s‘t’ test 
            ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
   
 
                                      Graph12: Effect of HAREWS on TNF-α 
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                                         Table14: Effect of HAREWS on Interleukin-6 
 
 
                    Values are represented in Mean ± SEM, n=6 
                   Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
     Statistical significance test for comparison was done by one way ANOVA 
followed by Dunnet’s‘t’ test 
ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
         
 
                                  Graph13: Effect of HAREWS on IL-6 
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                  SLNo. 
                
             Treatment  
 
       Interleukin  
 
                      1 
 
Normal saline  
 
   2.16±0.45 
                 
                      2 
 
Negative control (PPA) 
 
2.54±0.31ns 
                
                      3 
 
HAREWS200mg/kg 
 
1.61±0.39** 
            
                      4 
 
HAREWS400mg/kg 
 
1.46±0.26ns 
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                            Table15: Effect of HAREWS on Superoxide dismutase 
        
 
Sl.no 
 
Treatment 
SOD 
(Units mg/wet tissue) 
 
1 
 
Normal saline 
 
5.96±0.34 
 
2 
 
Negative control(PPA) 
 
3.54±0.19 a*** 
 
3 
 
HAREWS200mg/kg 
 
4.52±0.20 ns 
 
4 
 
HAREWS 400mg/kg 
 
5.22±0.09ns 
 
 
              Values are represented in Mean ± SEM, n=6 
              Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
Statistical significance test for comparison was done by one way ANOVA followed 
by Dunnet’s‘t’ test 
 
             ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
 
                               Graph14: Effect of HAREWS on Superoxide dismutase 
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                                       Table16: Effect of HAREWS on Catalase  
 
 
Sl.no 
 
Treatment 
Catalase 
(Units mg/wet tissue) 
 
1 
 
Normal saline 
 
6.25±0.17 
 
2 
 
Negative control(PPA) 
 
3.47±0.15a *** 
 
3 
 
HAREWS 200mg/kg 
 
4.79±0.27b*** 
 
4 
 
HAREWS 400mg/kg 
 
5.83±0.22b*** 
 
 
        Values are represented in Mean ± SEM, n=6 
        Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
  Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s‘t’ test 
            ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
 
 
                  Graph15: Effect of HAREWS on Catalase  
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                                  Table17:  Effect of HAREWS on Lipid peroxide  
  
 
 
          Values are represented in Mean ± SEM, n=6 
         Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
 Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s‘t’ test         
            ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
 
 
                         Graph16: Effect of HAREWS on Lipid Peroxide 
    
 
 
 
  
 
 
Sl.no 
 
Treatment 
Lipid peroxide 
(Units mg/wet tissue) 
 
1 
 
Normal saline 
 
6.84±0.38 
 
 
2 
 
Negative control(PPA) 
 
3.88±0.19a*** 
 
3 
 
HAREWS 200mg/kg 
 
6.16±0.18ns 
 
4 
 
HAREWS 400mg/kg 
 
5.96±0.37ns 
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                                Table 18: Effect of HAREWS on Glutathione Peroxidase 
 
 
 
               Values are represented in Mean ± SEM, n=6 
              Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
Statistical significance test for comparison was done by one way ANOVA followed 
by Dunnet’s‘t’ test 
            ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
 
 
                       Graph 17: Effect of HAREWS on Glutathione peroxidase 
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Sl.no Treatment Glutathione peroxidase 
(Units mg/wet tissue) 
1 Normal saline 6.85±0.20 
2 Negative control(PPA) 3.07±0.28a*** 
3 HAREWS 200mg/kg 5.56±0.20b*** 
4 HAREWS 400mg/kg 6.56±0.14b*** 
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               Table 19:  Effect of HAREWS on Glutathione Reductase 
 
 
Sl.no 
 
Treatment 
Glutathione reductase 
(Units mg/wet tissue) 
 
1 
 
Normal saline 
 
6.75±0.19 
 
2 
 
Negative control(PPA) 
 
3.25±0.15a*** 
 
3 
 
HAREWS 200mg/kg 
 
4.80±0.153b*** 
 
4 
 
HAREWS 400mg/kg 
 
5.72±0.22b*** 
 
 
             Values are represented in Mean ± SEM, n=6 
             Comparison: a- Group I vs Group II, b- Group II vs Group III and Group IV 
 Statistical significance test for comparison was done by one way ANOVA followed 
by Dunnet’s‘t’ test.              
            ns- Non significant, *p<0.05, **p<0.01, *p<0.001 
 
 
 
                  Graph18: Effect of HAREWS on Glutathione Reductase  
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7.10     HISTOPATHOLOGY 
                                             Fig 8a: control group 
 
 
                                        Fig8b: Negative control 
 
 
                                                 Fig8c: HAREWS200mg/kg 
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Fig8d:   HAREWS400mg/kg  
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8. DISCUSSION  
     Autism is a neurodevelopment disorder which is characterized by impaired social 
interaction, verbal and non-verbal communication and repetitive behavior. The investigative 
criteria require that symptoms became apparent in early childhood, typically before three year 
age. Autism is highly heritable diseases, researcher suspect both genetic fact as well as 
environmental fact as causes, in rare case autism is strongly related with agent that causes 
birth defect. 
  ASD is also known as pervasive developmental disorder which includes Asperger’s 
syndrome, Rett’s syndrome, Childhood Disintegrative Disorder, Autistic disorder and PDD-
NOS (Pervasive Developmental Disorder Not Otherwise Specified). It is characterized by 
impairments in three domains, specifically communication, social interaction and behaviors 
that are restricted and repetitive in nature.  
Childhood is a key developmental phase; with exacerbation of many ASD linked 
symptoms. Propionic acid is connected with ASD. A separation of ASD patients with 
gastrointestinal symptoms and behavioural regression have superior levels of Clostridia, an 
early gut colonizer known to produce PPA and other short chain fatty acids. ICV injections of 
PPA on rodent’s brain induced repetitive behaviours, hyperactivity, turning behaviour, 
retropulsion, caudate spiking, kindled seizures, impaired social behaviour, poor memory, 
increased oxidative stress markers, and induced an inherent neuroinflammatory response all 
of which appear consistent with findings from ASD patients. 
The present study has exposed the therapeutical effect of HAREWS on object directed 
behaviour, social behaviour and neuro-inflammation against PPA induced ASD in mice  PPA 
induced ASD was assessed by various parameters such as locomotory activity, nociception 
threshold, object directed behaviour, novel mice vs. novel object directed behaviour, Elevated 
plus maze, Morris Water maze test. 
Test on open field measured the locomotory activity, repetitive/stereotypic behaviour of mice. 
The animals that are induced with ASD by propionic acid showed staggering and toe walk. The 
animals are found to hyperactive with repetitive/stereotypic activity.  HAREWS treated animals 
showed the reversed behaviours. 
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Nociception threshold is analysed by tail flick method where the tail of animals were 
exposed to the high temperature water to induce pain. Animals which are normal respond more 
quickly to the pain. Mice with ASD showed delayed response to the heat as seen in ASD patients who 
possess high threshold to pain. Animals treated with HAREWS showed usual threshold like control 
mice representing that drug maintains the normal response to pain sensitivity 
Social behaviour of animals was tested by exploring the same with novel mice and an 
object. Normal mice are always expected to explore the novel mice rather than the object. 
Mice of PPA treated groups does not approached novel mice as they lack social interaction. 
Those that are pretreated with HAREWS showed significant increase in their interaction with 
novel mice as like normal mice, indicating that the drug under the present study improves the 
social interaction. 
Elevated plus maze task has been extended to measure the anxiety behaviour of the 
animal. The method was based on the fact that sudden exposure of animals to the higher 
altitude in open field induces anxiety, where the normal animals preferentially seek the closed 
arms than the open arm. Animals that are induced with ASD did not showed significant 
increased or decreased anxiety when compared to normal mice. 
The Morris water maze represents a more specific test of spatial memory. The 
essential feature of this technique is that mice were placed into a large circular pool of water 
and can escape onto a hidden platform. Since the platform offers no spatial cues to guide 
escape behaviour and the mouse can escape only from swimming by climbing onto the 
platform apparently learns the spatial location of the platform where ever the starting position 
may be. The only spatial cues are those outside water tank are primary visual cues. Thus, the 
flexibility of the task makes it a widely adequate experimental model for the assessment of 
cognitive skills. Typically, ASD mice took much time for escape indicating the lack of 
remembering visual cues to escape onto the platform. Such a diminished cognition was 
reversed by the administration of HAREWS and exhibited decreased escape latency (EL), 
indicating the well developed spatial memory inspite of PPA induced cognition deficits. 
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Serotonin is the critical neurotransmitter modulating short term habituation. 
Decreased level of serotonin is associated with repetitive/stereotypic behaviour and feeling of 
unhappiness. Serotonergic effects have also been detected on the region implicated in 
memory storage. Brain of ASD mice was observed to have decreased level of serotonin. 
Those that are treated with HAREWS increased brain serotonin level indicating the 
improvement in repetitive behaviour and cognition skill.  
TNF-α is a pro-inflammatory cell signaling protein involved in inflammation and is 
one of the cytokines that make up the acute phase reaction. It is produced chiefly by 
activated macrophages, although it can be produced by many other cell types such as CD4+ 
lymphocytes, NK cells, neutrophils, mast cells and neurons. Mice with ASD showed 
significant increase in brain TNF-α level indicating neuro-inflammation. Group of animals 
that are pretreated with HAREWS reduced the TNF-α level that indicates that it possesses 
anti-inflammatory activity. 
Interleukin-6 is a pro-inflammatory cytokines has an important role in immunity. IL-6 
induces growth and terminal differentiation of β-cells; secretion of immune-globulins, 
differentiation and activation of T-cells & macrophage. Many types of cells including T-cells, 
fibroblast & endothelial cell produce IL-6 to stimuli such as bacteria, viruses and other 
cytokines. Mice with ASD showed significant increase in brain IL-6 level indicating neuro-
inflammation. Animals which are pretreated with HAREWS reduced the IL-6 level that 
indicates it possess the anti-inflammatory activity. 
The brain is highly sensitive to oxidative damage because of its high oxygen 
consumption. Thus, oxidative biomarkers such as superoxide dismutase (CAT), catalase 
(CAT), glutathione peroxidase (GPx) and glutathione reductase (GRD), lipid peroxidase 
(LPO) are analysed to study the severity of the disorder and effect of the drug on it. Level of 
SOD, CAT, GPx and GRD were found to be decreased ASD affected mice and LPO was 
observed to be high in its concentration when compared to normal mice. The mice those were 
treated with HAREWS were observed to possess antioxidant activity showing the level of 
above mentioned oxidative biomarkers similar to normal mice. 
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9. SUMMARY 
                     The preliminary phytochemical studies on HAREWS discovered the presence of 
various phytoconstituents such as alkaloid, carbohydrates, glycosides, steroid, proteins, 
flavonoids and saponin. 
                   The habituation behavior of HAREWS on PPA induced ASD assessed by 
objective directed behavior; novel mice vs. novel object directed behavior, nociception 
threshold, elevated plus maze task and cognition development assessed by Morris water maze 
task. 
 The habituation behavior on open field revealed that HAREWS significantly 
reversed stereotypic and staggering movement. Memory retention was assessed on Morris 
water maze and HAREWS found greatly improved/enhanced the spatial memory. On 
HAREWS treatment the pain threshold was maintained as like normal subjects. Both 
propionic acid and HAREWS has found not to possess significant anxiety activity. 
 The biochemical changes that are responsible for stereotypic activity, cognition 
impairment, and neuro inflammation were assessed by estimating serotonin, TNF-α, 
Interleukin-6 respectively. HAREWS provided favorable effect on these above biochemicals. 
 The antioxidants defense in the brain tissues were estimated in terms of SOD, CAT, 
LPO, GPx, GRD and HAREWS increased the antioxidant levels at respective dose leading to 
reduce oxidative stress. This clearly indicates the potential of the extract to delay the 
generation of free radicals that cause neuronal damage. 
 The histopathology of ASD mice showed increased in neuron number and reduced 
size as seen in ASD patients. Whereas the control and HAREWS treated mice showed normal 
level of neuronal size and counts. 
 
 
10. CONCLUSION 
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              The present study demonstrated that ICV-infusion of propionic acid induced autism 
spectrum disorder in mice. Hydro-alcoholic root extract of Withania somnifera helps in 
improving object directed behavior, social behavior and cognitive skill. And also improve the 
neuro-inflammation. It also showed the anti-oxidant property which act as a neruo-protective. 
 Further studies are expected on the isolated components of the extract in order to 
understand the exact mechanism of its action and also studies at cellular level changes by 
more sophisticated methods for investigation. 
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